Page last updated: 2024-08-02 10:04:38

nu 7026

Description

2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source [MeSH]

2-(4-morpholinyl)-4-benzo[h][1]benzopyranone : no description available [CHeBI]

Cross-References

ID Source	ID
PubMed CID	9860529
CHEMBL ID	104468
SCHEMBL ID	610237
CHEBI ID	92165
MeSH ID	M0456818

Synonyms (58)

Synonym
BRD-K09537769-001-01-6
HSCI1_000223
NCGC00165840-01
CU-00000000014-1
nu7026
ly293646
2-(morpholin-4-yl)-benzo[h]chromen-4-one
dna-pk inhibitor ii
nu-7026
2-(morpholin-4-yl)benzo(h)chromen-4-one
nu 7026 ,
CHEMBL104468 ,
ly-293646
HMS3229C11
2-morpholino-4h-benzo[h]chromen-4-one
2-morpholin-4-yl-benzo[h]chromen-4-one
bdbm50098126
AKOS015994580
154447-35-5
BCP9001001
BCP0726000029
S2893
2-(4-morpholinyl)-4h-naphthol[1,2-b]pyran-4-one
gtpl5959
2-(morpholin-4-yl)-4h-benzo[h]chromen-4-one
CCG-206743
HY-15719
CS-1532
SCHEMBL610237
ES-0046
2-morpholin-4-ylbenzo[h]chromen-4-one
AC-32827
2-(4-morpholinyl)-4h-naphtho[1,2-b]pyran-4-one
DTXSID10432010
mfcd06798345
2-(4-morpholinyl)-4h-naphtho[1,2-b]pyran-4-one, nu7026
EX-A1100
CHEBI:92165
nu7026, >=98% (hplc), solid
J-506082
2-(morpholin-4-yl)benzo[h]chromen-4-one
FT-0701904
BCP04736
dna-pk inhibitor ii - cas 154447-35-5
HMS3675M22
ly 293646
dj7rqt66h6 ,
unii-dj7rqt66h6
Q27088097
HMS3411M22
BRD-K09537769-001-02-4
HMS3673C05
HMS3742M17
NCGC00165840-11
2-morpholino-4h-benzo(h)chromen-4-one
2-(4-morpholinyl)-4h-naphtho(1,2-b)pyran-4-one
4h-naphtho(1,2-b)pyran-4-one, 2-(4-morpholinyl)-
2-morpholinobenzo[h]chromen-4-one

Drug Classes (2)

Class	Description
organooxygen compound	An organochalcogen compound containing at least one carbon-oxygen bond.
organic heterotricyclic compound	An organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.

Protein Targets (9)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	44.6684	AID485290
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	35.4813	AID2546
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	26.6795	AID588579

Inhibition Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)	IC50	13.0000	AID325654
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	IC50	13.0000	AID1189519; AID241543; AID241782
Serine/threonine-protein kinase mTOR	Homo sapiens (human)	IC50	6.4000	AID241331; AID241385; AID593234
DNA-dependent protein kinase catalytic subunit	Homo sapiens (human)	IC50	0.2388	AID1189523; AID241618; AID241691; AID257403; AID325644; AID57384; AID593233; AID604392
Serine-protein kinase ATM	Homo sapiens (human)	IC50	100.0000	AID241720; AID242483; AID325749; AID593232
Serine/threonine-protein kinase ATR	Homo sapiens (human)	IC50	100.0000	AID241617; AID242484; AID325750; AID593187

Bioassays (565)

Assay ID	Title	Year	Journal	Article
AID720274	Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID257403	Inhibitory activity against DNA-dependent protein kinase receptor	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24 ISSN: 0022-2623	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.
AID720405	Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720273	Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720457	Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720373	Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720171	Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720164	Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720200	Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720477	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720126	Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720052	Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720391	Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720246	Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID57384	In vitro inhibition of DNA-dependent protein kinase(DNA-PK) from HeLa (human carcinoma) cells.	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18 ISSN: 0960-894X	2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK).
AID720047	Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224793	Delta TM value showing the stabilisation of RSK2a produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720168	Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720342	Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720214	Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720081	Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720277	Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720283	Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720361	Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720278	Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720411	Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720398	Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID241617	Inhibition of Ataxia telangiectasia related protein ATR kinase	2004	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 ISSN: 0960-894X	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
AID720125	Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720217	Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720145	Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720032	Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720036	Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720459	Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720445	Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID242483	Inhibition of ATM kinase using rabbit polyclonal antisera; No inhibition observed at 100 uM	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 ISSN: 0022-2623	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
AID1224773	Delta TM value showing the stabilisation of ASK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720176	Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720282	Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID241331	Inhibition of mTOR protein isolated from HeLa cells	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 ISSN: 0022-2623	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
AID720261	Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720375	Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720202	Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720175	Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720400	Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720307	Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224777	Delta TM value showing the stabilisation of MST4(1) produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720159	Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720243	Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224775	Delta TM value showing the stabilisation of ERK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720119	Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720385	Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720331	Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720291	Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720420	Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720429	Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720428	Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224755	Delta TM value showing the stabilisation of CAMK4 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720216	Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224768	Delta TM value showing the stabilisation of DMPK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224801	Delta TM value showing the stabilisation of MST1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720209	Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720064	Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224800	Delta TM value showing the stabilisation of MST4 (2) produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720182	Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720074	Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720463	Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID593187	Inhibition of full length recombinant ATR after 24 hrs by radiometric phosphate incorporation assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7 ISSN: 1520-4804	Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID720094	Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720318	Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720225	Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720227	Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720046	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720154	Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720212	Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720305	Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720396	Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720446	Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224770	Delta TM value showing the stabilisation of JAK1~B produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720390	Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720022	Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720053	Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224792	Delta TM value showing the stabilisation of RIOK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224795	Delta TM value showing the stabilisation of SLK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224806	Delta TM value showing the stabilisation of VRK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720253	Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720031	Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720129	Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1189519	Inhibition of PI3K p110alpha (unknown origin)	2015	Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1 ISSN: 1520-4804	Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.
AID720451	Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720423	Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720263	Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720452	Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720077	Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720122	Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720378	Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720376	Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720344	Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720189	Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720296	Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720067	Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1189523	Inhibition of DNA-PK purified from human HeLa nuclear extracts	2015	Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1 ISSN: 1520-4804	Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.
AID1224776	Delta TM value showing the stabilisation of ERK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720352	Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720023	Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720091	Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720112	Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720232	Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720281	Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720323	Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720073	Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720219	Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325772	Plasma clearance in mouse at 5 mg/kg, iv	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720458	Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224796	Delta TM value showing the stabilisation of LOK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720425	Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224750	Delta TM value showing the stabilisation of CAMK1G produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720464	Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720417	Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720310	Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720165	Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720237	Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720397	Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720466	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720208	Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720408	Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720117	Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720021	Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720211	Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720421	Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720160	Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720295	Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720204	Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720389	Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720462	Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720324	Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720201	Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720430	Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID241720	Inhibition of Mutated in ataxia telangiectasia protein ATM kinase	2004	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 ISSN: 0960-894X	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
AID720329	Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720454	Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720020	Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720304	Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325654	Inhibition of PI3K	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720136	Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224772	Delta TM value showing the stabilisation of MAP2K6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720070	Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720133	Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224759	Delta TM value showing the stabilisation of CDKL1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720440	Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720194	Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720195	Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720259	Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720269	Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224786	Delta TM value showing the stabilisation of PIM1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720026	Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720169	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1189525	Selectivity ratio of IC50 for PI3K p110alpha (unknown origin) to IC50 for DNA-PK purified from HeLa nuclear extracts	2015	Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1 ISSN: 1520-4804	Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.
AID720317	Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224785	Delta TM value showing the stabilisation of PDK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID546568	Inhibition of DNA-PK isolated from human HeLa cell extract assessed as reduction in p53 Ser15 phosphorylation by chemiluminescence assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 ISSN: 1520-4804	DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.
AID720308	Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720374	Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224774	Delta TM value showing the stabilisation of p38beta produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID241543	Inhibition of Phosphatidylinositol 3-kinase	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 ISSN: 0022-2623	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
AID720229	Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720062	Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720447	Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720357	Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720336	Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720358	Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID241782	Inhibition of Phosphatidylinositol 3-kinase p110 alpha subunit	2004	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 ISSN: 0960-894X	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
AID720196	Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720362	Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720424	Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720292	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720364	Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720303	Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720018	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720106	Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720403	Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720027	Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720158	Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720144	Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720340	Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720231	Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720328	Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720355	Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720468	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720333	Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720435	Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720066	Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720206	Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720101	Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720326	Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720092	Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224781	Delta TM value showing the stabilisation of PAK4 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720134	Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720341	Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720234	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID155499	Inhibition of Phoshoinositol 3 kinase	2001	Bioorganic & medicinal chemistry letters, Apr-09, Volume: 11, Issue:7 ISSN: 0960-894X	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family.
AID720247	Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224802	Delta TM value showing the stabilisation of TNIK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID593233	Inhibition of DNAPK after 2 hrs by radiometric phosphate incorporation assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7 ISSN: 1520-4804	Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID720121	Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720135	Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224807	Delta TM value showing the stabilisation of YSK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720239	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720384	Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720313	Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720260	Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1849032	Inhibition of DMH-1 induced cardiogenesis in mouse embryonic stem cells transfected with Myh6-GFP at 0.05 to 5 uM pretreated with compound followed by DMH-1 stimulation for 24 hrs in the presence of BMP-4 with replacement of media on day 7 and 9 and measu	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22 ISSN: 1520-4804	Phenotypic Discovery of Triazolo[1,5-
AID720072	Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720393	Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720250	Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID241618	Inhibitory activity against DNA-dependent protein kinase (DNA-PK)	2004	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 ISSN: 0960-894X	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
AID720139	Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720181	Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720392	Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720215	Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720461	Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720190	Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720382	Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720173	Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720387	Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720184	Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720399	Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720299	Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720330	Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720321	Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224789	Delta TM value showing the stabilisation of PLK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720167	Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720469	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720161	Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325644	Inhibition of DNA-PK	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720087	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720083	Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720025	Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224761	Delta TM value showing the stabilisation of CLK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720042	Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720131	Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720264	Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720262	Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720322	Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720276	Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720054	Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720418	Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720252	Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720056	Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720147	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720104	Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720148	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720038	Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720157	Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224749	Delta TM value showing the stabilisation of CAMK1D produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720043	Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720383	Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224798	Delta TM value showing the stabilisation of DRAK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720426	Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720419	Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720090	Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720479	Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720163	Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224748	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720363	Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720050	Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720151	Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720044	Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720359	Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720210	Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720394	Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720235	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720350	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720114	Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720284	Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224751	Delta TM value showing the stabilisation of CAMK2A produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720093	Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224762	Delta TM value showing the stabilisation of CLK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720224	Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720439	Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID241385	Inhibition of Mammalian target of Rapamycin mTOR	2004	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 ISSN: 0960-894X	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
AID720116	Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720256	Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720432	Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720346	Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720041	Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720017	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720320	Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224778	Delta TM value showing the stabilisation of NEK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720453	Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325773	Bioavailability in mouse at 20 mg/kg, ip	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720416	Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720480	Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720441	Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720203	Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720240	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720221	Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720343	Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720474	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720483	Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720078	Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720471	Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720415	Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720353	Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224765	Delta TM value showing the stabilisation of CK1G2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720233	Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720431	Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720097	Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720213	Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325774	Bioavailability in mouse at 20 mg/kg, po	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720412	Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720319	Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720061	Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720030	Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720084	Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720413	Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720095	Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720109	Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720080	Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720337	Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720286	Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720314	Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720242	Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720049	Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720110	Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720174	Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720140	Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224784	Delta TM value showing the stabilisation of PCTK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720172	Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720115	Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720395	Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224764	Delta TM value showing the stabilisation of CK1G1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720185	Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720096	Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720404	Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224804	Delta TM value showing the stabilisation of VRK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720285	Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720045	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720146	Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224758	Delta TM value showing the stabilisation of CDK6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720444	Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720188	Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720228	Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224791	Delta TM value showing the stabilisation of PRKACA produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224790	Delta TM value showing the stabilisation of PLK4 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720082	Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720434	Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720223	Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720348	Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224756	Delta TM value showing the stabilisation of CAMKK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720245	Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720422	Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720098	Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720338	Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720205	Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720244	Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720124	Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720179	Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720162	Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720152	Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720118	Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720207	Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720316	Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720409	Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720455	Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720280	Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720339	Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720220	Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720294	Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720226	Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224752	Delta TM value showing the stabilisation of CAMK2B produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720287	Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720075	Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID241691	Inhibition of DNA dependent protein kinase isolated from HeLa cells	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 ISSN: 0022-2623	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
AID720369	Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720137	Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720414	Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID604392	Inhibition of DNA-PK	2011	Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13 ISSN: 1464-3391	Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines.
AID720306	Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720470	Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720089	Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224753	Delta TM value showing the stabilisation of CAMK2D produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720065	Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720386	Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720302	Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720029	Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720460	Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720438	Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720068	Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720132	Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720113	Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720360	Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720351	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720187	Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720057	Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224794	Delta TM value showing the stabilisation of RSK2b produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720289	Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325750	Inhibition of ATR	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720347	Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720265	Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720105	Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720035	Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720372	Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720366	Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720327	Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720475	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720311	Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720107	Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1849030	Induction of osteogenic differentiation in mouse C2C12 cells assessed as ALP activity preincubated with compound in the presence of BMP-4 for 72 hrs followed by substrate addition and measured after 1 hrs by luminescence based assay	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22 ISSN: 1520-4804	Phenotypic Discovery of Triazolo[1,5-
AID720051	Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720178	Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720481	Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID593232	Inhibition of full length recombinant ATM after 24 hrs by radiometric phosphate incorporation assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7 ISSN: 1520-4804	Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID1224805	Delta TM value showing the stabilisation of VRK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720266	Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720332	Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224799	Delta TM value showing the stabilisation of NDR1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720484	Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224783	Delta TM value showing the stabilisation of PAK6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720478	Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224782	Delta TM value showing the stabilisation of PAK5 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720297	Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720467	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720033	Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720039	Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720267	Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720086	Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720138	Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720465	Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720365	Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720275	Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720060	Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720437	Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224779	Delta TM value showing the stabilisation of NEK6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720197	Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720088	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720183	Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720315	Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID593234	Inhibition of mTOR by radiometric phosphate incorporation assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7 ISSN: 1520-4804	Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID720334	Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720130	Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720180	Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720300	Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720379	Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720108	Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720111	Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720024	Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720443	Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720156	Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720436	Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720407	Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224797	Delta TM value showing the stabilisation of MPSK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720103	Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720325	Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720127	Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720312	Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720069	Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720141	Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224763	Delta TM value showing the stabilisation of CLK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720034	Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720290	Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720230	Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720456	Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720055	Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720354	Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720293	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720442	Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224771	Delta TM value showing the stabilisation of MEK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720288	Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720371	Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID242484	Inhibition of ATR kinase using rabbit polyclonal antisera; No inhibition observed at 100 uM	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2 ISSN: 0022-2623	Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
AID720448	Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720079	Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720476	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720150	Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720401	Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720058	Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720177	Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720270	Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720222	Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720335	Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720085	Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720153	Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720236	Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720368	Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224757	Delta TM value showing the stabilisation of CDK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720298	Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720309	Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720199	Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224767	Delta TM value showing the stabilisation of DAPK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720059	Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720193	Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720170	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720218	Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720071	Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720370	Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720048	Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224760	Delta TM value showing the stabilisation of CHEK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224787	Delta TM value showing the stabilisation of PIM2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720102	Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720268	Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720377	Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720191	Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720301	Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720123	Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224754	Delta TM value showing the stabilisation of CAMK2G produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224788	Delta TM value showing the stabilisation of PIM3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224803	Delta TM value showing the stabilisation of PBK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720028	Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720120	Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720406	Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720381	Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224766	Delta TM value showing the stabilisation of CK1G3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720367	Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720186	Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720155	Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720345	Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720037	Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720272	Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720166	Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720040	Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720472	Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720019	Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720402	Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720063	Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720473	Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720356	Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720249	Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325749	Inhibition of ATM	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224780	Delta TM value showing the stabilisation of OSR1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720254	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720410	Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720143	Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720076	Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720251	Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720198	Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720099	Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720142	Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720258	Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720257	Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720248	Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720482	Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720100	Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720388	Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720128	Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720450	Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720449	Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720349	Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720149	Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720255	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720241	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720192	Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720380	Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720427	Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224769	Delta TM value showing the stabilisation of GSK3B produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51 ISSN: 1091-6490	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720279	Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720271	Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720433	Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720238	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 ISSN: 1464-3391	Highly predictive and interpretable models for PAMPA permeability.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14 ISSN: 1464-3391	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1 ISSN: 2045-2322	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346204	Human DNA-dependent protein kinase catalytic subunit (Other PIKK family kinases)	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18 ISSN: 0960-894X	2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK).

Research

Studies (69)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (23.19)	29.6817
2010's	48 (69.57)	24.3611
2020's	5 (7.25)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (1.43%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	69 (98.57%)	84.16%

Substance	Classes	Roles	Relationship Strength
2-carboxyethyl gamma-aminobutyric acid	organonitrogen compound; organooxygen compound		low
carcinine	beta-alanine derivative; imidazoles; monocarboxylic acid amide; organonitrogen compound; organooxygen compound	antioxidant; crustacean metabolite	low
dimethyl pyrocarbonate	organooxygen compound		low
methoxyamine	organooxygen compound		low
nialamide	organonitrogen compound; organooxygen compound		low
oxiracetam	organonitrogen compound; organooxygen compound		low
piracetam	organonitrogen compound; organooxygen compound		low
etozolin	organonitrogen compound; organooxygen compound		low
2-acetyltributylcitrate	organooxygen compound		low
guanidine carboxamide	organooxygen compound		low
cuprizone	organonitrogen compound; organooxygen compound		low
cdta	organooxygen compound		low
alpha-fluoro-beta-alanine	organonitrogen compound; organooxygen compound		low
ammonium bicarbonate	organooxygen compound		low
4-amino-3-phenylbutyric acid	organonitrogen compound; organooxygen compound		low
zinc carbonate	organooxygen compound		low
nicofuranose	organooxygen compound		low
lodoxamide	organonitrogen compound; organooxygen compound		low
Arbaclofen	organonitrogen compound; organooxygen compound		low
pramiracetam	organonitrogen compound; organooxygen compound		low
etiracetam	organooxygen compound		low
azidoamphenicol	organonitrogen compound; organooxygen compound		low
telmesteine	organonitrogen compound; organooxygen compound		low
pivagabine	organonitrogen compound; organooxygen compound		low
nefiracetam	organonitrogen compound; organooxygen compound		low
betamipron	organonitrogen compound; organooxygen compound		low
2-carboxythiazolidine-4-carboxylic acid	organonitrogen compound; organooxygen compound		low
alpha-lapachone	organic heterotricyclic compound; organooxygen compound		low
5,5-dimethylthiazolidine-4-carboxylic acid	organonitrogen compound; organooxygen compound		low
aurofusarin	organic heterotricyclic compound; organooxygen compound		low
7,9-dimethyl-9aH-quinolizine-1,2,3,4-tetracarboxylic acid tetramethyl ester	organooxygen compound		low
n-nitrosothiazolidine-4-carboxylic acid	organonitrogen compound; organooxygen compound		low
pyridinoline	organonitrogen compound; organooxygen compound		low
4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide	organonitrogen compound; organooxygen compound		low
paspaline	organic heterotricyclic compound; organooxygen compound		low
2-methyl-5-nitroimidazol-1-ylacetic acid	organonitrogen compound; organooxygen compound		low
3-carboxymethyl-6-benzyl-2,5-diketopiperazine	organonitrogen compound; organooxygen compound		low
3,5-diiodothyronine	organonitrogen compound; organooxygen compound		low
8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline	organonitrogen compound; organooxygen compound		low
salvinorin a	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen	low
merodantoin	organonitrogen compound; organooxygen compound		low
sch 45752	organic heterotricyclic compound; organooxygen compound		low
argininic acid	organonitrogen compound; organooxygen compound		low
delta-guanidinovaleric acid	organonitrogen compound; organooxygen compound		low
chlorocarbonic acid	organooxygen compound		low
byssochlamic acid	organooxygen compound		low
mirestrol	organic heterotricyclic compound; organooxygen compound		low
isoputreanine	organonitrogen compound; organooxygen compound		low
cyclo(glycylprolyl)	organonitrogen compound; organooxygen compound		low
cyclo(tyrosyl-prolyl)	organonitrogen compound; organooxygen compound		low
columbin	organic heterotricyclic compound; organooxygen compound		low
N-cyclopropyl-N-[2-[(4-methoxyphenyl)methylamino]-2-oxo-1-thiophen-2-ylethyl]-4-thiadiazolecarboxamide	organonitrogen compound; organooxygen compound		low
N-[2-(cyclopentylamino)-1-(5-methyl-2-furanyl)-2-oxoethyl]-N-[(4-fluorophenyl)methyl]-4-thiadiazolecarboxamide	organonitrogen compound; organooxygen compound		low
N-[2-(cyclohexylamino)-1-(2-furanyl)-2-oxoethyl]-N-(2-furanylmethyl)-2-furancarboxamide	organonitrogen compound; organooxygen compound		low
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(thiophen-2-ylmethyl)amino]-2-(2-furanyl)-N-(3-methylbutyl)acetamide	organonitrogen compound; organooxygen compound		low
N-butan-2-yl-N-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-4-thiadiazolecarboxamide	organonitrogen compound; organooxygen compound		low
N'-[2-(cyclohexylamino)-2-oxoethyl]-N-(5-methyl-3-isoxazolyl)-N'-phenylpentanediamide	organonitrogen compound; organooxygen compound		low
N-[2-(5-chloro-2-methoxyanilino)-2-oxoethyl]-N-cyclohexyl-2-furancarboxamide	organonitrogen compound; organooxygen compound		low
2-(N-[2-(1-benzotriazolyl)-1-oxoethyl]-4-methoxyanilino)-N-(2-methylbutan-2-yl)-2-(1-methyl-2-pyrrolyl)acetamide	organonitrogen compound; organooxygen compound		low
2-(N-[2-(1-benzotriazolyl)-1-oxoethyl]-4-methylanilino)-N-(2-furanylmethyl)-2-(3-pyridinyl)acetamide	organonitrogen compound; organooxygen compound		low
N-[2-(tert-butylamino)-2-oxo-1-pyridin-4-ylethyl]-N-cyclopropyl-4-thiadiazolecarboxamide	organonitrogen compound; organooxygen compound		low
N-cyclopentyl-2-[2-oxolanylmethyl-(1-oxo-2-thiophen-2-ylethyl)amino]-2-thiophen-2-ylacetamide	organonitrogen compound; organooxygen compound		low
N'-[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]-N'-(3-fluorophenyl)-N-(3-pyridinyl)butanediamide	organonitrogen compound; organooxygen compound		low
2-(2,4-dioxo-3-thiazolidinyl)-N-(2,3,4-trifluorophenyl)acetamide	organonitrogen compound; organooxygen compound		low
N-tert-butyl-2-(2-furanyl)-2-[[2-[5-(5-methyl-2-furanyl)-2-tetrazolyl]-1-oxoethyl]-(thiophen-2-ylmethyl)amino]acetamide	organonitrogen compound; organooxygen compound		low
N'-[1-[(cyclohexylamino)-oxomethyl]cyclopentyl]-N-(5-methyl-3-isoxazolyl)-N'-phenylbutanediamide	organonitrogen compound; organooxygen compound		low
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-propan-2-ylamino]-2-(2,5-dimethoxyphenyl)-N-(2-furanylmethyl)acetamide	organonitrogen compound; organooxygen compound		low
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(2-furanylmethyl)amino]-N-cyclohexyl-2-(2-fluorophenyl)acetamide	organonitrogen compound; organooxygen compound		low
N'-[2-(cyclopentylamino)-2-oxoethyl]-N'-(3,4-dimethylphenyl)-N-(2-pyridinyl)pentanediamide	organonitrogen compound; organooxygen compound		low
N-(1,3-benzodioxol-5-yl)-N-[1-(4-chlorophenyl)-2-(cyclohexylamino)-2-oxoethyl]-2-pyrazinecarboxamide	organonitrogen compound; organooxygen compound		low
2-[(3-methyl-2,4-dioxo-5-thiazolidinyl)amino]benzoic acid	organonitrogen compound; organooxygen compound		low
4-amino-N5-[2-(2-methoxyethylamino)-1-(5-methyl-2-furanyl)-2-oxoethyl]-N5-(thiophen-2-ylmethyl)isothiazole-3,5-dicarboxamide	organonitrogen compound; organooxygen compound		low
N'-[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]-N-(5-methyl-3-isoxazolyl)-N'-phenylbutanediamide	organonitrogen compound; organooxygen compound		low
2-[1,3-benzodioxol-5-yl-[2-(1-benzotriazolyl)-1-oxoethyl]amino]-N-(2-methoxyethyl)-2-thiophen-2-ylacetamide	organonitrogen compound; organooxygen compound		low
1-[2-[cyano-(4,6-dimethyl-2-pyrimidinyl)amino]-1-oxoethyl]-4-piperidinecarboxamide	organonitrogen compound; organooxygen compound		low
4-[3-(4-methoxyanilino)-3-oxopropyl]-1-piperazinecarboxylic acid ethyl ester	organonitrogen compound; organooxygen compound		low
3-[[(5-bromo-3-pyridinyl)-oxomethyl]amino]propanoic acid	organonitrogen compound; organooxygen compound		low
N-(2,4-dimethoxyphenyl)-3-(4-morpholinyl)propanamide	organonitrogen compound; organooxygen compound		low
1-[[2-(3-methylanilino)-1-oxoethyl]amino]-3-phenylthiourea	organonitrogen compound; organooxygen compound		low
2-oxo-3-benzo[h][1]benzopyrancarboxylic acid ethyl ester	organic heterotricyclic compound; organooxygen compound		low
1-(2,3-dimethyl-1-indolyl)-2-(4-methyl-1-piperidinyl)ethanone	organonitrogen compound; organooxygen compound		low
1-(N-[2-(Benzotriazol-1-yl)acetyl]-4-methoxyanilino)-N-cyclopentylcyclohexane-1-carboxamide	organonitrogen compound; organooxygen compound	anticoronaviral agent	low
4-(4-methylphenyl)-2-[[3-(4-morpholinyl)-1-oxopropyl]amino]-3-thiophenecarboxylic acid ethyl ester	organonitrogen compound; organooxygen compound		low
3-imino-2-benzo[f][1]benzopyrancarbothioamide	organic heterotricyclic compound; organooxygen compound		low
3-(3-oxo-2-benzo[f][1]benzopyranyl)-1-phenyl-4-pyrazolecarboxaldehyde	organic heterotricyclic compound; organooxygen compound		low
2-[(4-fluorophenyl)hydrazo]-2-oxoacetic acid ethyl ester	organonitrogen compound; organooxygen compound		low
4-[(3,5-dimethylphenyl)-oxomethyl]-1,3-dihydroquinoxalin-2-one	organonitrogen compound; organooxygen compound		low
N-(3,5-dimethoxyphenyl)-2-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolyl)acetamide	organonitrogen compound; organooxygen compound		low
5-[(2-chlorophenyl)hydrazo]-3,3-bis(hydroxymethyl)-2H-1,4-oxazin-6-one	organonitrogen compound; organooxygen compound		low
2-[(3-acetyl-5-oxo-4H-imidazol-2-yl)thio]-N-(4-methyl-5-phenyl-2-thiazolyl)-N-prop-2-enylacetamide	organonitrogen compound; organooxygen compound		low
2-[(3-acetyl-5-oxo-4H-imidazol-2-yl)thio]-N-(4,5-diphenyl-2-thiazolyl)acetamide	organonitrogen compound; organooxygen compound		low
2-chloro-N-[3-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-3-oxopropyl]benzamide	organonitrogen compound; organooxygen compound		low
4-bromo-N-[3-oxo-3-(2-thiazolylamino)propyl]benzamide	organonitrogen compound; organooxygen compound		low
N-[3-[4-[(2-methoxyphenyl)sulfamoyl]anilino]-3-oxopropyl]-2-furancarboxamide	organonitrogen compound; organooxygen compound		low
3-(4-Chloroanilino)propanoic acid	organonitrogen compound; organooxygen compound		low
1,4-dihydroxy-4a,5,6,7,8,8a-hexahydroquinoxaline-2,3-dione	organonitrogen compound; organooxygen compound		low
2-(2-furanyl)-4-thiazolidinecarboxylic acid	organonitrogen compound; organooxygen compound		low
methyl-thiohydantoin-tryptophan	organonitrogen compound; organooxygen compound		low
2-(difluoromethyl)-4-benzo[h][1]benzopyranone	organic heterotricyclic compound; organooxygen compound		low
3-hydroxy-7-methyl-3-(4-morpholinyl)-5-nitro-1H-indol-2-one	organonitrogen compound; organooxygen compound		low
5-bromo-3-hydroxy-3-(4-methyl-1-piperidinyl)-1H-indol-2-one	organonitrogen compound; organooxygen compound		low
N-(3,4-dimethylphenyl)-2-(4-methylanilino)-6-oxo-4,5-dihydro-1H-pyrimidine-4-carboxamide	organonitrogen compound; organooxygen compound		low
N-(3-chloro-4-methylphenyl)-4-oxo-3,10-dihydro-2H-pyrimido[1,2-a]benzimidazole-2-carboxamide	organonitrogen compound; organooxygen compound		low
N-[2-(1-azepanyl)-2-oxoethyl]-N-[(4-chlorophenyl)methyl]methanesulfonamide	organonitrogen compound; organooxygen compound		low
2-[1-[[[(3-chloro-1-benzothiophen-2-yl)-oxomethyl]amino]-sulfanylidenemethyl]-3-oxo-2-piperazinyl]acetic acid methyl ester	organonitrogen compound; organooxygen compound		low
2-(2-methoxy-2-oxoethyl)-3-oxo-1-piperazinecarboxylic acid tert-butyl ester	organonitrogen compound; organooxygen compound		low
albutoin	organonitrogen compound; organooxygen compound		low
2-thioxo-4-thiazolidinecarboxylic acid	organonitrogen compound; organooxygen compound		low
momilactone b	organic heterotricyclic compound; organooxygen compound		low
N-[[2-(4-chlorophenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]benzenesulfonamide	organonitrogen compound; organooxygen compound		low
4-methyl-2-[3-methyl-4-(3-methylphenyl)azo-5-oxo-4H-pyrazol-1-yl]-5-thiazolecarboxylic acid ethyl ester	organonitrogen compound; organooxygen compound		low
5'-(4-methylphenyl)-2-spiro[1H-indole-3,2'-3H-1,3,4-thiadiazole]one	organonitrogen compound; organooxygen compound		low
N-[2-(cyclopentylamino)-1-(4-fluorophenyl)-2-oxoethyl]-N-[(4-fluorophenyl)methyl]-1H-pyrazole-5-carboxamide	organonitrogen compound; organooxygen compound		low
N-[2-(cyclopentylamino)-1-(3,4-dimethoxyphenyl)-2-oxoethyl]-N-[(4-fluorophenyl)methyl]-1H-pyrazole-5-carboxamide	organonitrogen compound; organooxygen compound		low
uccf-029	organic heterotricyclic compound; organooxygen compound		low
2-(2-furanyl)-2-[(4-methoxyphenyl)methyl-[2-[5-(5-methyl-2-furanyl)-2-tetrazolyl]-1-oxoethyl]amino]-N-(2-oxolanylmethyl)acetamide	organonitrogen compound; organooxygen compound		low
2-[cyclopentyl-[1-oxo-2-(5-thiophen-2-yl-2-tetrazolyl)ethyl]amino]-N-(2-oxolanylmethyl)-2-thiophen-2-ylacetamide	organonitrogen compound; organooxygen compound		low
2-(N-[2-(Benzotriazol-1-yl)acetyl]-2,4,6-trimethylanilino)-N-tert-butyl-2-thiophen-3-ylacetamide	organonitrogen compound; organooxygen compound	anticoronaviral agent	low
CID 3206295	organonitrogen compound; organooxygen compound	anticoronaviral agent	low
N-tert-butyl-2-[(2-chloro-1-oxoethyl)-(2-furanylmethyl)amino]-2-(4-chlorophenyl)acetamide	organonitrogen compound; organooxygen compound		low
N'-(1,3-benzodioxol-5-ylmethyl)-N'-[2-(cyclopentylamino)-2-oxoethyl]-N-(5-methyl-3-isoxazolyl)butanediamide	organonitrogen compound; organooxygen compound		low
2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(3-pyridinyl)amino]-2-(4-chlorophenyl)-N-(2-methoxyethyl)acetamide	organonitrogen compound; organooxygen compound		low
N-cyclohexyl-2-(4-fluoro-N-[1-oxo-2-(3-thiophenyl)ethyl]anilino)-2-(4-fluorophenyl)acetamide	organonitrogen compound; organooxygen compound		low
1-(2-methyl-2,3-dihydroindol-1-yl)-2-[4-[5-(trifluoromethyl)-1-benzotriazolyl]-1-piperidinyl]ethanone	organonitrogen compound; organooxygen compound		low
5-bromo-N-[2-(2,3-dihydroindol-1-yl)-2-oxoethyl]-N-methyl-2-thiophenesulfonamide	organonitrogen compound; organooxygen compound		low
N-cyclopentyl-3-[(4-methylphenyl)sulfonylamino]propanamide	organonitrogen compound; organooxygen compound		low
2-[(5-bromo-2-thiophenyl)sulfonyl-methylamino]-N-(6-methyl-1,3-benzothiazol-2-yl)acetamide	organonitrogen compound; organooxygen compound		low
3-[(4-methoxyphenyl)sulfonylamino]-N-(phenylmethyl)propanamide	organonitrogen compound; organooxygen compound		low
2-(4-methyl-1-oxo-[1]benzothiolo[2,3-d]pyridazin-2-yl)propanoic acid	organonitrogen compound; organooxygen compound		low
3-amino-4-(1,3-benzothiazol-2-yl)-N-(3-chloro-2-methylphenyl)-5-phenylimino-2H-thiophene-2-carboxamide	organonitrogen compound; organooxygen compound		low
6-amino-5-cyano-4-(2-fluorophenyl)-2-sulfanylidene-3,4-dihydro-1H-pyridine-3-carboxamide	organonitrogen compound; organooxygen compound		low
N-(5-chloro-2-methoxyphenyl)-2-pyridin-4-yl-4,5-dihydrothiazole-4-carboxamide	organonitrogen compound; organooxygen compound		low
2-(N-(2-chloro-1-oxoethyl)-3-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide	organonitrogen compound; organooxygen compound		low
2-(N-(2-chloro-1-oxoethyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide	organonitrogen compound; organooxygen compound		low
LSM-1924	organic heterotricyclic compound; organooxygen compound		low
LSM-16912	organonitrogen compound; organooxygen compound		low
N-(4-phenylmethoxyphenyl)-3-[4-(phenylmethyl)-1-piperazinyl]propanamide	organonitrogen compound; organooxygen compound		low
3,6-bis[(1H-indol-3-yl)methyl]piperazine-2,5-dione	organonitrogen compound; organooxygen compound		low
LSM-22738	organic heterotricyclic compound; organooxygen compound		low
N-[1-(cyclopentylamino)-2-methyl-1-oxobutan-2-yl]-N-(thiophen-2-ylmethyl)-2-pyridinecarboxamide	organonitrogen compound; organooxygen compound		low
N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(2-furanylmethyl)-2-pyridinecarboxamide	organonitrogen compound; organooxygen compound		low
N-[1-(cyclohexylamino)-2-methyl-1-oxobutan-2-yl]-N-(2-furanylmethyl)-2-pyridinecarboxamide	organonitrogen compound; organooxygen compound		low
N-[6-amino-2,4-dioxo-1-(phenylmethyl)-5-pyrimidinyl]-N-ethyl-2-(2-methyl-2,3-dihydroindol-1-yl)acetamide	organonitrogen compound; organooxygen compound		low
N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(thiophen-2-ylmethyl)-2-pyrazinecarboxamide	organonitrogen compound; organooxygen compound		low
1-[2-(4-methoxyphenyl)-4-[oxo(1-pyrrolidinyl)methyl]-3-thiazolidinyl]-1-propanone	organonitrogen compound; organooxygen compound		low
LSM-26445	organic heterotricyclic compound; organooxygen compound		low
2-(N-(2-chloro-1-oxoethyl)-4-fluoroanilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide	organonitrogen compound; organooxygen compound		low
2-(N-(2-chloro-1-oxoethyl)-4-methoxyanilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide	organonitrogen compound; organooxygen compound		low
2-(3-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide	organonitrogen compound; organooxygen compound		low
2-(2,3-dioxo-1-indolyl)-N-(2-phenylethyl)acetamide	organonitrogen compound; organooxygen compound		low
N-[5-(phenylmethyl)-2-thiazolyl]-4,5-dihydro-1H-imidazole-2-carboxamide	organonitrogen compound; organooxygen compound		low
LSM-1925	organic heterotricyclic compound; organooxygen compound		low
2-[[(3-amino-4-carbamoyl-5-cyclohexylimino-2H-thiophen-2-yl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid methyl ester	organonitrogen compound; organooxygen compound		low
3-amino-N2-(2,3-dichlorophenyl)-5-(2-methoxyphenyl)imino-2H-thiophene-2,4-dicarboxamide	organonitrogen compound; organooxygen compound		low
5'-bromo-2'-spiro[1,2-dihydro-4,1,2-benzoxadiazine-3,3'-1H-indole]one	organonitrogen compound; organooxygen compound		low
N-(3,4-dimethylphenyl)-4-oxo-3,10-dihydro-2H-pyrimido[1,2-a]benzimidazole-2-carboxamide	organonitrogen compound; organooxygen compound		low
LSM-25964	organic heterotricyclic compound; organooxygen compound		low
N-(3-oxo-2-benzo[f][1]benzopyranyl)acetamide	organic heterotricyclic compound; organooxygen compound		low
N-(5,5-dimethyl-7-oxo-4,6-dihydro-1,3-benzothiazol-2-yl)-2-(2,5-dioxo-1-pyrrolidinyl)acetamide	organonitrogen compound; organooxygen compound		low
N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(thiophen-2-ylmethyl)-2-pyridinecarboxamide	organonitrogen compound; organooxygen compound		low
chicoric acid	organooxygen compound	geroprotector; HIV-1 integrase inhibitor	low
1-[2-(4-morpholinyl)-2-oxoethyl]-2-pyrido[2,3-b][1,4]thiazinone	organonitrogen compound; organooxygen compound		low
aurantiamine	organonitrogen compound; organooxygen compound		low
5-aminolevulinic acid hexyl ester	organonitrogen compound; organooxygen compound		low
gabalid	organonitrogen compound; organooxygen compound		low
tremortin a	organic heterotricyclic compound; organooxygen compound		low
N-[3-[(1,3-dimethyl-2,6-dioxo-4-pyrimidinyl)methylamino]-3-oxopropyl]-3-methoxybenzamide	organonitrogen compound; organooxygen compound		low
4-chloro-N-[4-[3-(methylthio)anilino]-4-oxobutyl]benzamide	organonitrogen compound; organooxygen compound		low
N-[2-(2,6-dichloroanilino)-2-oxoethyl]-N-methyl-4-pyridinecarboxamide	organonitrogen compound; organooxygen compound		low
N-[2-(4-chlorophenyl)ethyl]-2-[3-[(2-fluorophenyl)methyl]-2-oxo-1-imidazolidinyl]acetamide	organonitrogen compound; organooxygen compound		low
2-[3-[(2-chloro-4-fluorophenyl)methyl]-2-oxo-1,3-diazinan-1-yl]-N-cyclooctylacetamide	organonitrogen compound; organooxygen compound		low
seletracetam	organonitrogen compound; organooxygen compound		low
terpendole e	organic heterotricyclic compound; organooxygen compound		low
elagolix	organonitrogen compound; organooxygen compound		low
citrinadin a	organonitrogen compound; organooxygen compound		low
moiramide b	organonitrogen compound; organooxygen compound		low
N-[(1,3-dioxo-2-phenyl-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl)methyl]-4-methylbenzenesulfonamide	organonitrogen compound; organooxygen compound		low
lc15-0444	organonitrogen compound; organooxygen compound		low
2-(3-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(4-methoxyphenyl)acetamide	organonitrogen compound; organooxygen compound		low
2-(4-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(4-methoxyphenyl)acetamide	organonitrogen compound; organooxygen compound		low
2-[(2-chloro-1-oxoethyl)-(2,2-dimethoxyethyl)amino]-2-(4-chlorophenyl)-N-cyclohexylacetamide	organonitrogen compound; organooxygen compound		low
1-(4-fluorophenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea	organonitrogen compound; organooxygen compound		low
1-(4-methylphenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea	organonitrogen compound; organooxygen compound		low
1-(3-chlorophenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea	organonitrogen compound; organooxygen compound		low
N-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]-4-phenyl-1-piperazinecarbothioamide	organonitrogen compound; organooxygen compound		low
3-acetamido-N-[4-(4-methylsulfonylphenyl)-2-thiazolyl]-3-phenyl-N-prop-2-enylpropanamide	organonitrogen compound; organooxygen compound		low
thallusin	organic heterotricyclic compound; organooxygen compound		low
3-[4-[2-(2-fluorophenyl)ethylamino]-3-nitrophenyl]-3-[[2-(1-naphthalenyl)-1-oxoethyl]amino]propanamide	organonitrogen compound; organooxygen compound		low
aflatrem	organic heterotricyclic compound; organooxygen compound		low
N-[(2-ethoxyphenyl)methyl]-3-[(2-oxo-3H-1,3-benzoxazol-6-yl)sulfonylamino]propanamide	organonitrogen compound; organooxygen compound		low
(3S)-3-(2-methylpropyl)-4-oxo-3-phenyldiazetidine-1,2-dicarboxylic acid dimethyl ester	organonitrogen compound; organooxygen compound		low
(3S)-3-(4-methoxyphenyl)-4-oxo-3-propan-2-yldiazetidine-1,2-dicarboxylic acid dimethyl ester	organonitrogen compound; organooxygen compound		low
(3S)-4-oxo-3-phenyl-3-propan-2-yldiazetidine-1,2-dicarboxylic acid dimethyl ester	organonitrogen compound; organooxygen compound		low
(3S)-3-cyclopentyl-4-oxo-3-phenyldiazetidine-1,2-dicarboxylic acid dimethyl ester	organonitrogen compound; organooxygen compound		low
(3R)-3-(4-chlorophenyl)-4-oxo-3-propan-2-yldiazetidine-1,2-dicarboxylic acid diethyl ester	organonitrogen compound; organooxygen compound		low
LSM-1873	organic heterotricyclic compound; organooxygen compound		low
LSM-1834	organic heterotricyclic compound; organooxygen compound		low
LSM-1287	organic heterotricyclic compound; organooxygen compound		low
LSM-1675	organic heterotricyclic compound; organooxygen compound		low
LSM-1312	organic heterotricyclic compound; organooxygen compound		low
LSM-1315	organic heterotricyclic compound; organooxygen compound		low
gsk 1838705a	organonitrogen compound; organooxygen compound		low
3-(4-fluorophenylethylamino)-1-methyl-4-(2-methyl-1h-indol-3-yl)-1h-pyrrole-2,5-dione	maleimides; organonitrogen compound; organooxygen compound		low
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	organonitrogen compound; organooxygen compound		low
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	organonitrogen compound; organooxygen compound		low
N-[(2S,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	organonitrogen compound; organooxygen compound		low
neosurugatoxin	organonitrogen compound; organooxygen compound		low
3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-phenoxybutoxy)phenyl)propoxy)benzoic acid	organonitrogen compound; organooxygen compound		low
putreanine	carboxylic acid anion; N-substituted putrescine; organonitrogen compound; organooxygen compound		low
santacruzamate a	organonitrogen compound; organooxygen compound		low
8-epidiosbulbin e acetate	organic heterotricyclic compound; organooxygen compound		low
2-[(2-oxo-3-indolyl)amino]-N-(2-phenylethyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	organonitrogen compound; organooxygen compound		low
pterine-6-carboxylic acid	organonitrogen compound; organooxygen compound		low
conocurvone	organic heterotricyclic compound; organooxygen compound		low
phosphocreatinine	organonitrogen compound; organooxygen compound		low
5-methoxypsoralen	5-methoxyfurocoumarin; organic heterotricyclic compound; psoralens	hepatoprotective agent; plant metabolite	low
beta-naphthoflavone	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist	low
etodolac	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	low
fluorescite	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium	low
ketotifen	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist	low
khellin	furanochromone; organic heterotricyclic compound; oxacycle	anti-asthmatic agent; bronchodilator agent; cardiovascular drug; vasodilator agent	low
oxolinic acid	aromatic carboxylic acid; organic heterotricyclic compound; oxacycle; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antifungal agent; antiinfective agent; antimicrobial agent; enzyme inhibitor	low
ro 15-4513	organic heterotricyclic compound; organonitrogen heterocyclic compound		low
skimmianine	alkaloid antibiotic; organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
benzo(b)naphtho(2,1-d)thiophene	organic heterotricyclic compound; organosulfur heterocyclic compound		low
kokusaginine	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
cytisine	alkaloid; bridged compound; lactam; organic heterotricyclic compound; secondary amino compound	nicotinic acetylcholine receptor agonist; phytotoxin; plant metabolite	low
alpha-naphthoflavone	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist; aryl hydrocarbon receptor antagonist; EC 1.14.14.14 (aromatase) inhibitor	low
naftalofos	organic heterotricyclic compound	anthelminthic drug	low
helenalin	cyclic ketone; gamma-lactone; organic heterotricyclic compound; secondary alcohol; sesquiterpene lactone	anti-inflammatory agent; antineoplastic agent; metabolite; plant metabolite	low
ancitabine	diol; organic heterotricyclic compound	antimetabolite; antineoplastic agent; prodrug	low
1-(3-chloro-5-benzo[b][1]benzoxepinyl)-4-methylpiperazine	N-alkylpiperazine; organic heterotricyclic compound		low
colforsin	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist	low
nedocromil	dicarboxylic acid; organic heterotricyclic compound	anti-allergic agent; anti-asthmatic drug; non-steroidal anti-inflammatory drug	low
naxagolide	organic heterotricyclic compound; phenols; tertiary amino compound	anticonvulsant; antiparkinson drug; dopamine agonist	low
depsidone	depsidones; organic heterotricyclic compound		low
droxicam	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug	low
dictamnine	alkaloid antibiotic; organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
flindersiamine	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
flindersine	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
maculine	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
zaluzanin C	gamma-lactone; guaiane sesquiterpenoid; organic heterotricyclic compound; secondary alcohol; sesquiterpene lactone	EC 1.14.13.39 (nitric oxide synthase) inhibitor; metabolite	low
dehydrocostus lactone	gamma-lactone; guaiane sesquiterpenoid; organic heterotricyclic compound; sesquiterpene lactone	antimycobacterial drug; antineoplastic agent; apoptosis inducer; cyclooxygenase 2 inhibitor; metabolite; trypanocidal drug	low
Evoxine	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
galaxolide	isochromenes; organic heterotricyclic compound	fragrance	low
geographutoxin i	organic heterotricyclic compound	marine metabolite	low
gamma-fagarine	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
1,9-dideoxyforskolin	acetate ester; labdane diterpenoid; organic heterotricyclic compound	plant metabolite	low
pannarin	aldehyde; aromatic ether; depsidones; organic heterotricyclic compound; organochlorine compound; phenols	antimicrobial agent; antineoplastic agent; apoptosis inducer; lichen metabolite	low
confertin	cyclic ketone; gamma-lactone; organic heterotricyclic compound; pseudoguaianolide	anti-inflammatory agent; metabolite; plant metabolite	low
inuviscolide	gamma-lactone; organic heterotricyclic compound; sesquiterpene lactone; tertiary alcohol	anti-inflammatory agent; plant metabolite	low
ergolide	acetate ester; cyclic ketone; gamma-lactone; organic heterotricyclic compound; sesquiterpene lactone	anti-inflammatory agent; antineoplastic agent; metabolite; NF-kappaB inhibitor; plant metabolite	low
fk 1052	imidazoles; organic heterotricyclic compound	antiemetic; serotonergic antagonist	low
noscapine	aromatic ether; benzylisoquinoline alkaloid; cyclic acetal; isobenzofuranone; organic heterobicyclic compound; organic heterotricyclic compound; tertiary amino compound	antineoplastic agent; antitussive; apoptosis inducer; plant metabolite	low
aromaticin	cyclic ketone; gamma-lactone; organic heterotricyclic compound; sesquiterpene lactone	anti-inflammatory agent; metabolite; plant metabolite	low
rocaglamide	monocarboxylic acid amide; monomethoxybenzene; organic heterotricyclic compound	antileishmanial agent; antineoplastic agent; metabolite	low
aglafoline	methyl ester; organic heterotricyclic compound	metabolite; platelet aggregation inhibitor	low
cimifugin	organic heterotricyclic compound; oxacycle		low
khelloside	organic heterotricyclic compound; oxacycle		low
decursinol	cyclic ether; delta-lactone; organic heterotricyclic compound; secondary alcohol	analgesic; antineoplastic agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite	low
cleomiscosin a	aromatic ether; delta-lactone; organic heterotricyclic compound; phenols; primary alcohol	anti-inflammatory agent; metabolite	low
Dubinidine	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
colforsin daropate	acetate ester; carboxylic ester; cyclic ketone; diol; organic heterotricyclic compound; tertiary amino compound	adenylate cyclase agonist; antihypertensive agent; cardiotonic drug; vasodilator agent	low
thapsigargin	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor	low
reynosin	organic heterotricyclic compound; sesquiterpene lactone	metabolite	low
5',7'-dimethylspiro[cyclohexane-1,3'-pyrimido[5,4-c][1,2,5]oxadiazine]-6',8'-dione	organic heterotricyclic compound; spiro compound		low
vedelianin	cyclic ether; organic heterotricyclic compound; resorcinols; stilbenoid	antineoplastic agent; plant metabolite	low
haplamine	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
(2R)-1-[(4,8-dimethoxy-7-furo[2,3-b]quinolinyl)oxy]-3-methylbutane-2,3-diol	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
acetic acid (11-oxo-6H-benzo[c][1]benzoxepin-2-yl) ester	organic heterotricyclic compound		low
huperzine a	organic heterotricyclic compound; primary amino compound; pyridone; sesquiterpene alkaloid	EC 3.1.1.7 (acetylcholinesterase) inhibitor; neuroprotective agent; nootropic agent; plant metabolite	low
CHIC-35	aromatic compound; organic heterotricyclic compound; organochlorine compound; primary carboxamide	EC 3.5.1.98 (histone deacetylase) inhibitor	low
2-benzamido-4,5-dihydrobenzo[g][1]benzothiole-3-carboxamide	organic heterotricyclic compound; organosulfur heterocyclic compound		low
2-benzo[b][1]benzoxepinamine	organic heterotricyclic compound		low
LSM-33589	organic heterotricyclic compound; organosulfur heterocyclic compound		low
bigelovin	acetate ester; cyclic ketone; gamma-lactone; organic heterotricyclic compound; sesquiterpene lactone	antineoplastic agent; apoptosis inducer; immunomodulator; plant metabolite	low
quinagolide	organic heterotricyclic compound; organonitrogen heterocyclic compound		low
6,8-difluoro-4-(pyridin-3-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline	organic heterotricyclic compound; organofluorine compound; pyridines; secondary amino compound		low
4-[oxo-(4-oxo-5H-thieno[3,2-c]quinolin-2-yl)methyl]-1-piperazinecarboxylic acid ethyl ester	organic heterotricyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		low
[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-(7-methoxy-2-furo[2,3-b]quinolinyl)methanone	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
1-[(6-methoxy-2-furo[2,3-b]quinolinyl)-oxomethyl]-4-piperidinecarboxylic acid ethyl ester	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
N-[2-(dipropylamino)ethyl]-4-methyl-2-furo[3,2-c]quinolinecarboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
6-methoxy-N-(thiophen-2-ylmethyl)-2-furo[2,3-b]quinolinecarboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
7-methoxy-N-(3-pyridinylmethyl)-2-furo[2,3-b]quinolinecarboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
acetic acid [1-[(4,8-dimethoxy-7-furo[2,3-b]quinolinyl)oxy]-3-hydroxy-3-methylbutan-2-yl] ester	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
chanoclavine	benzoindole; ergot alkaloid; organic heterotricyclic compound; primary alcohol; secondary amino compound		low
riddelliine	macrodiolide; olefinic compound; organic heterotricyclic compound; pyrrolizine alkaloid	carcinogenic agent; genotoxin; mutagen	low
irilone	hydroxyisoflavone; organic heterotricyclic compound; oxacycle	antineoplastic agent; immunomodulator; metabolite	low
heliparvifoline	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
sirolimus	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor	low
5-ethyl-4-oxo-N-(thiophen-2-ylmethyl)-2-thieno[3,2-c]quinolinecarboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		low
8-methyl-1-[2-(2-methyl-1-piperidinyl)-2-oxoethyl]-4-[1]benzopyrano[4,3-c]pyrazolone	organic heterotricyclic compound		low
cytochalasin b	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor	low
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone	morpholines; naphthyl ketone; organic heterotricyclic compound; synthetic cannabinoid	analgesic; apoptosis inhibitor; neuroprotective agent	low
methyl brevifolincarboxylate	cyclic ketone; delta-lactone; organic heterotricyclic compound; phenols	EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; metabolite; platelet aggregation inhibitor; radical scavenger; vasodilator agent	low
palonosetron	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist	low
himbacine	gamma-lactone; organic heterotricyclic compound; piperidine alkaloid	muscarinic antagonist	low
riddelliine n-oxide	diol; macrocyclic lactone; olefinic compound; organic heterotricyclic compound; primary alcohol; pyrrolizine alkaloid; tertiary alcohol; tertiary amine oxide	carcinogenic agent; genotoxin; human xenobiotic metabolite; Jacobaea metabolite; mutagen; rat metabolite	low
chaetoviridin a	azaphilone; beta-hydroxy ketone; enone; gamma-lactone; organic heterotricyclic compound; organochlorine compound; secondary alcohol	antifungal agent; Chaetomium metabolite	low
4-methyl-N-[(4-methylphenyl)methyl]-2-furo[3,2-c]quinolinecarboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
beraprost	enyne; monocarboxylic acid; organic heterotricyclic compound; secondary alcohol; secondary allylic alcohol	anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent	low
jwh-133	benzochromene; dibenzopyran; organic heterotricyclic compound	analgesic; anti-inflammatory agent; antineoplastic agent; apoptosis inhibitor; CB2 receptor agonist; opioid analgesic; vasodilator agent	low
pi103	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	low
epicocconone	organic heterotricyclic compound	fluorochrome	low
pentalenolactone f	alpha,beta-unsaturated monocarboxylic acid; organic heterotricyclic compound; sesquiterpene lactone; spiro-epoxide	bacterial metabolite	low
jnj16259685	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
episilvestrol	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite	low
silvestrol	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite	low
4-chloro-N-(3,4-dimethoxyphenyl)-2-thieno[3,2-c]quinolinecarboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		low
monascin	alpha,beta-unsaturated ketone; gamma-lactone; organic heterotricyclic compound; polyketide	antilipemic drug; antineoplastic agent; fungal metabolite; PPARgamma agonist	low
batzelladine a	alkaloid; carboxylic ester; guanidines; organic heterotricyclic compound; pyrrolopyrimidine; triazaacenaphthylene	anti-HIV-1 agent; metabolite	low
prim-o-glucosylcimifugin	organic heterotricyclic compound; oxacycle		low
4-chloro-N-[3-(3-methyl-1-piperidinyl)propyl]-2-thieno[3,2-c]quinolinecarboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		low
schweinfurthin g	cyclic ether; organic heterotricyclic compound; resorcinols; stilbenoid	antineoplastic agent; metabolite	low
8-methyl-4-oxo-N-[3-(4-propyl-1-piperazinyl)propyl]-5H-thieno[3,2-c]quinoline-2-carboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		low
N,8-dimethyl-N-(3-methylphenyl)-4-oxo-5H-thieno[3,2-c]quinoline-2-carboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		low
N-[2-(dipropylamino)ethyl]-5-ethyl-4-oxo-2-thieno[3,2-c]quinolinecarboxamide	organic heterotricyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		low
schweinfurthin f	cyclic ether; organic heterotricyclic compound; resorcinols; stilbenoid	metabolite	low
dihydroagarofuran	bridged compound; cyclic ether; eudesmane sesquiterpenoid; organic heterotricyclic compound	metabolite	low
4'-epichaetoviridin A	azaphilone; beta-hydroxy ketone; enone; gamma-lactone; organic heterotricyclic compound; organochlorine compound; secondary alcohol	Chaetomium metabolite	low
arenaemycin e	alpha,beta-unsaturated monocarboxylic acid; organic heterotricyclic compound; sesquiterpene lactone; spiro-epoxide	antimicrobial agent; bacterial metabolite; EC 1.2.1.12 [glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)] inhibitor	low
mk 2206	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
chaetoviridin E	azaphilone; enone; gamma-lactone; organic heterotricyclic compound; organochlorine compound	Chaetomium metabolite	low
debromoaplysiatoxin	aplysiatoxins; cyclic hemiketal; ether; organic heterotricyclic compound; phenols; secondary alcohol; spiroketal	algal metabolite; carcinogenic agent; cyanotoxin; marine metabolite; protein kinase C agonist	low
aplysiatoxin	aplysiatoxins; bromophenol; cyclic hemiketal; ether; organic heterotricyclic compound; secondary alcohol; spiroketal	algal metabolite; carcinogenic agent; cyanotoxin; marine metabolite; protein kinase C agonist	low
gonyautoxin v	organic heterotricyclic compound; paralytic shellfish toxin	marine metabolite	low
4-hydroxy-6-propan-2-ylpyrano[3,2-c]quinoline-2,5-dione	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle		low
gsk1265744	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor	low
dolutegravir	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor	low
pelabresib	monochlorobenzenes; organic heterotricyclic compound; primary carboxamide	antineoplastic agent; bromodomain-containing protein 4 inhibitor	low
gonyautoxin ii	organic heterotricyclic compound; paralytic shellfish toxin	marine metabolite	low
scytonemin	enone; organic heterotricyclic compound; organonitrogen heterocyclic compound; polyphenol; ring assembly	bacterial metabolite; biological pigment; ultraviolet filter	low
liproxstatin-1	azaspiro compound; monochlorobenzenes; organic heterotricyclic compound; secondary amino compound	antioxidant; cardioprotective agent; ferroptosis inhibitor; radical scavenger	low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's	post-2020
b 844-39	1	diarylmethane		2017	2017	7.0	low	0	1	0
pk 11195	3	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent	2017	2020	5.3	low	0	3	0
pd 173074	1	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	2007	2007	17.0	low	1	0	0
4,5,6,7-tetrabromo-2-azabenzimidazole	1			2007	2007	17.0	low	1	0	0
jtv519	3			2017	2020	5.3	high	0	3	0
N-(2-aminoethyl)-5-chloro-1-naphthalenesulfonamide	1	naphthalenes; sulfonic acid derivative		2007	2007	17.0	low	1	0	0
tyrphostin ag 1024	1	alkylbenzene		2013	2013	11.0	low	0	1	0
ag 1295	2	quinoxaline derivative	geroprotector	2007	2013	14.0	medium	1	1	0
ag-1296	1	quinoxaline derivative		2013	2013	11.0	low	0	1	0
rtki cpd	1	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector	2013	2013	11.0	low	0	1	0
tyrphostin a23	1	catechols		2007	2007	17.0	low	1	0	0
tyrphostin a1	1	methoxybenzenes	geroprotector	2013	2013	11.0	low	0	1	0
alprazolam	3	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic	2017	2020	5.3	low	0	3	0
dan 2163	3	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic	2017	2020	5.3	low	0	3	0
amlexanox	3	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug	2017	2020	5.3	low	0	3	0
astemizole	3	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist	2017	2020	5.3	low	0	3	0
benzbromarone	3	1-benzofurans; aromatic ketone	uricosuric drug	2017	2020	5.3	low	0	3	0
bisindolylmaleimide i	5			2007	2020	8.8	low	1	4	0
bisindolylmaleimide iv	2	indoles; maleimides		2007	2013	14.0	medium	1	1	0
bohemine	2	purines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2007	2013	14.0	low	1	1	0
bufexamac	3	aromatic ether; hydroxamic acid	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2017	2020	5.3	low	0	3	0
cadralazine	3	organic molecular entity		2017	2020	5.3	low	0	3	0
caffeine	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic	2011	2011	13.0	low	0	1	0
carvedilol	2	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent	2019	2020	4.5	low	0	2	0
cetirizine	2	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic	2019	2020	4.5	low	0	2	0
cgs 15943	1	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant	2022	2022	2.0	low	0	0	1
chelerythrine	2	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2007	2013	14.0	low	1	1	0
chlorcyclizine	3	diarylmethane		2017	2020	5.3	low	0	3	0
ci 994	3	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	2017	2020	5.3	low	0	3	0
cyclosporine	2			2017	2020	5.5	high	0	2	0
damnacanthal	1	aldehyde; monohydroxyanthraquinone		2007	2007	17.0	low	1	0	0
r 59022	1	diarylmethane		2007	2007	17.0	low	1	0	0
n(6),n(6)-dimethyladenine	1	tertiary amine		2007	2007	17.0	low	1	0	0
ellipticine	1	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite	2007	2007	17.0	low	1	0	0
fenbendazole	3	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug	2017	2020	5.3	low	0	3	0
berotek	1	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent	2017	2017	7.0	low	0	1	0
gö6983	1	indoles; maleimides		2013	2013	11.0	low	0	1	0
go 6976	5	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor	2007	2020	8.8	low	1	4	0
ha 1004	1	isoquinolines		2007	2007	17.0	low	1	0	0
fasudil	2	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	2007	2013	14.0	low	1	1	0
haloperidol	3	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist	2017	2020	5.3	low	0	3	0
homochlorocyclizine	3	diarylmethane		2017	2020	5.3	low	0	3	0
hydroxyzine	3	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist	2017	2020	5.3	low	0	3	0
ifenprodil	3	piperidines		2017	2020	5.3	low	0	3	0
indirubin-3'-monoxime	2			2007	2013	14.0	low	1	1	0
whi p154	1			2013	2013	11.0	low	0	1	0
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone	4	naphthalenes		2013	2020	6.8	medium	0	4	0
nsc 664704	2	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector	2007	2013	14.0	low	1	1	0
ketamine	3	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic	2017	2020	5.3	low	0	3	0
ketoprofen	3	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic	2017	2020	5.3	low	0	3	0
lavendustin a	1	aromatic amine		2007	2007	17.0	low	1	0	0
2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acid	1	aromatic amine		2007	2007	17.0	low	1	0	0
ly 303511	1	N-arylpiperazine		2013	2013	11.0	low	0	1	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	8	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector	2001	2015	17.4	low	6	2	0
mebendazole	3	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator	2017	2020	5.3	low	0	3	0
mephenesin	3	aromatic ether; glycerol ether		2017	2020	5.3	low	0	3	0
ml 9	1	naphthalenes; sulfonic acid derivative		2007	2007	17.0	low	1	0	0
niclosamide	3	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor	2017	2020	5.3	low	0	3	0
nu6102	1			2007	2007	17.0	low	1	0	0
olomoucine	1	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2007	2007	17.0	low	1	0	0
oxibendazole	3	benzimidazoles; carbamate ester		2017	2020	5.3	low	0	3	0
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine	3			2017	2020	5.3	low	0	3	0
pd 153035	1	aromatic amine; aromatic ether; bromobenzenes; quinazolines; secondary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist	2007	2007	17.0	low	1	0	0
pd 158780	1	aromatic amine; bromobenzenes; diamine; pyridopyrimidine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	0	1	0
pd 169316	2	imidazoles		2007	2013	14.0	low	1	1	0
pd 98059	2	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2007	2013	14.0	low	1	1	0
perphenazine	3	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug	2017	2020	5.3	low	0	3	0
pimobendan	3	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent	2017	2020	5.3	low	0	3	0
1-NA-PP1	1	pyrazolopyrimidine	tyrosine kinase inhibitor	2007	2007	17.0	low	1	0	0
ag 1879	4	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector	2007	2020	8.2	low	1	3	0
1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine	1	pyrazoles; ring assembly		2013	2013	11.0	low	0	1	0
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one	2	indoles		2017	2020	5.5	medium	0	2	0
ro 31-8220	3	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor	2017	2020	5.3	low	0	3	0
ropinirole	3	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist	2017	2020	5.3	low	0	3	0
sb 220025	2	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2007	2013	14.0	low	1	1	0
sb 239063	1	imidazoles		2007	2007	17.0	low	1	0	0
sb 202190	2	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2007	2013	14.0	low	1	1	0
sk&f 86002	1	imidazoles		2013	2013	11.0	low	0	1	0
vorinostat	3	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2017	2020	5.3	low	0	3	0
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine	2	stilbenoid		2017	2020	5.5	high	0	2	0
trifluperidol	1	aromatic ketone		2017	2017	7.0	low	0	1	0
whi p180	1			2007	2007	17.0	low	1	0	0
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole	3	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent	2017	2020	5.3	low	0	3	0
zm 336372	1	benzamides		2007	2007	17.0	low	1	0	0
zotepine	3	dibenzothiepine; tertiary amino compound	alpha-adrenergic drug; second generation antipsychotic; serotonergic drug	2017	2020	5.3	low	0	3	0
dichlororibofuranosylbenzimidazole	1			2007	2007	17.0	low	1	0	0
colchicine	3	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen	2017	2020	5.3	low	0	3	0
benziodarone	3	aromatic ketone		2017	2020	5.3	low	0	3	0
cyclizine	1	N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; H1-receptor antagonist; local anaesthetic	2019	2019	5.0	low	0	1	0
trehalose	3	trehalose	Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2017	2020	5.3	low	0	3	0
triclocarban	3	dichlorobenzene; monochlorobenzenes; phenylureas	antimicrobial agent; antiseptic drug; disinfectant; environmental contaminant; xenobiotic	2017	2020	5.3	low	0	3	0
pyrazolanthrone	2	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector	2007	2013	14.0	low	1	1	0
1,4-naphthoquinone	1	1,4-naphthoquinones		2007	2007	17.0	low	1	0	0
4-tert-octylphenol	3	alkylbenzene		2017	2020	5.3	low	0	3	0
ethamivan	3	methoxybenzenes; phenols		2017	2020	5.3	low	0	3	0
methysergide	3	ergoline alkaloid		2017	2020	5.3	low	0	3	0
emetine	3	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor	2017	2020	5.3	low	0	3	0
podophyllotoxin	3	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator	2017	2020	5.3	low	0	3	0
flavone	1	flavones	metabolite; nematicide	2005	2005	19.0	low	1	0	0
alpha-naphthoflavone	1	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist; aryl hydrocarbon receptor antagonist; EC 1.14.14.14 (aromatase) inhibitor	2005	2005	19.0	low	1	0	0
etonitazene	3			2017	2020	5.3	low	0	3	0
clothiapine	3	dibenzothiazepine		2017	2020	5.3	low	0	3	0
benperidol	3	aromatic ketone		2017	2020	5.3	low	0	3	0
7-hydroxychlorpromazine	3	phenothiazines		2017	2020	5.3	medium	0	3	0
camptothecin	3	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite	2017	2020	5.3	low	0	3	0
thenalidine	3	dialkylarylamine; tertiary amino compound		2017	2020	5.3	medium	0	3	0
bromocriptine	3	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist	2017	2020	5.3	low	0	3	0
dexchlorpheniramine	3	chlorphenamine		2017	2020	5.3	low	0	3	0
dv 1006	3			2017	2020	5.3	medium	0	3	0
climbazole	3	aromatic ether; hemiaminal ether; imidazoles; ketone; monochlorobenzenes		2017	2020	5.3	low	0	3	0
triadimenol	3	aromatic ether; conazole fungicide; hemiaminal ether; monochlorobenzenes; secondary alcohol; triazole fungicide	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; xenobiotic metabolite	2017	2020	5.3	medium	0	3	0
staurosporine	2	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector	2007	2013	14.0	low	1	1	0
amonafide	3	isoquinolines		2017	2020	5.3	low	0	3	0
flupirtine	3	aminopyridine		2017	2020	5.3	low	0	3	0
chaetochromin	3			2017	2020	5.3	medium	0	3	0
enoximone	3	aromatic ketone		2017	2020	5.3	low	0	3	0
aripiprazole	3	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist	2017	2020	5.3	low	0	3	0
arctigenin	1	lignan		2007	2007	17.0	low	1	0	0
triciribine	1	nucleoside analogue	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	0	1	0
aloxistatin	1	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor	2019	2019	5.0	low	0	1	0
indocate	3			2017	2020	5.3	medium	0	3	0
N(4)-acetylsulfathiazole	3	1,3-thiazoles; acetamides; sulfonamide	marine xenobiotic metabolite	2017	2020	5.3	high	0	3	0
cyclizine hydrochloride	2			2017	2020	5.5	medium	0	2	0
2,3-trimethylene-4-quinazolone	3	quinazolines		2017	2020	5.3	medium	0	3	0
1,3-dimethyluric acid	3	oxopurine	metabolite	2017	2020	5.3	low	0	3	0
danofloxacin	3	quinolines		2017	2020	5.3	low	0	3	0
nitrefazole	3	imidazoles		2017	2020	5.3	medium	0	3	0
methotrimeprazine	3	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist	2017	2020	5.3	low	0	3	0
honokiol	3	biphenyls		2017	2020	5.3	low	0	3	0
chelerythrine chloride	1			2007	2007	17.0	low	1	0	0
9-methoxyellipticine	3			2017	2020	5.3	low	0	3	0
3-aminophenoxazone	3	phenoxazine		2017	2020	5.3	low	0	3	0
3-deazaneplanocin	3			2017	2020	5.3	low	0	3	0
fascaplysine	1			2007	2007	17.0	low	1	0	0
LSM-4272	1	beta-carbolines		2013	2013	11.0	low	0	1	0
tryptanthrine	3	alkaloid antibiotic; organic heterotetracyclic compound; organonitrogen heterocyclic compound		2017	2020	5.3	low	0	3	0
2-chlorodiazepam	3			2017	2020	5.3	medium	0	3	0
Polycartine B	3	phenazines		2017	2020	5.3	high	0	3	0
aminoquinuride dihydrochloride	3			2017	2020	5.3	high	0	3	0
thioproperazine mesylate	3	phenothiazines		2017	2020	5.3	medium	0	3	0
n(6)-(delta(2)-isopentenyl)adenine	3	6-isopentenylaminopurine	cytokinin	2017	2020	5.3	low	0	3	0
4-methyl-N-(phenylmethyl)benzenesulfonamide	3	sulfonamide		2017	2020	5.3	medium	0	3	0
5-iodotubercidin	1	organoiodine compound		2007	2007	17.0	low	1	0	0
zpck	2			2019	2020	4.5	low	0	2	0
sr141716	3	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist	2017	2020	5.3	low	0	3	0
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide	2	aromatic ketone		2017	2020	5.5	high	0	2	0
fingolimod	3	aminodiol; primary amino compound	antineoplastic agent; CB1 receptor antagonist; immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist	2017	2020	5.3	low	0	3	0
tesmilifene	3	diarylmethane		2017	2020	5.3	low	0	3	0
schizandrin b	1			2011	2011	13.0	low	0	1	0
sr 27897	3	indolyl carboxylic acid		2017	2020	5.3	low	0	3	0
imatinib mesylate	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	2007	2007	17.0	low	1	0	0
gefitinib	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	2007	2007	17.0	low	1	0	0
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine	3	leucine derivative		2017	2020	5.3	low	0	3	0
norketamine	3	organochlorine compound		2017	2020	5.3	low	0	3	0
indatraline	2	indanes		2019	2020	4.5	low	0	2	0
methotrexate	3	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent	2017	2020	5.3	low	0	3	0
salvinorin a	1	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen	2019	2019	5.0	low	0	1	0
2-(4-morpholinyl)-4h-1-benzopyran-4-one	3			2001	2005	20.7	high	3	0	0
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide	3			2017	2020	5.3	low	0	3	0
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide	3	phenylindole		2017	2020	5.3	low	0	3	0
l 741626	3	piperidines		2017	2020	5.3	low	0	3	0
dx 8951	3	pyranoindolizinoquinoline		2017	2020	5.3	low	0	3	0
vatalanib	1	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	2007	2007	17.0	low	1	0	0
ruboxistaurin	1			2007	2007	17.0	low	1	0	0
tipifarnib	3	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	2017	2020	5.3	low	0	3	0
cyc 202	4	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2007	2020	8.2	low	1	3	0
avasimibe	3	monoterpenoid		2017	2020	5.3	low	0	3	0
sb 203580	2	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent	2007	2013	14.0	low	1	1	0
erlotinib	1	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor	2007	2007	17.0	low	1	0	0
l 163191	3			2017	2020	5.3	low	0	3	0
dizocilpine	3	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist	2017	2020	5.3	low	0	3	0
s-benzylcysteine	3	S-aryl-L-cysteine zwitterion		2017	2020	5.3	high	0	3	0
chelidonine	3	alkaloid antibiotic; alkaloid fundamental parent; benzophenanthridine alkaloid		2017	2020	5.3	low	0	3	0
lapatinib	3	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	0	3	0
roxindole	3	indoles	alpha-adrenergic antagonist; serotonergic drug	2017	2020	5.3	low	0	3	0
conidendrin	3			2017	2020	5.3	high	0	3	0
Porfiromycine	3	mitomycin		2017	2020	5.3	high	0	3	0
nsc 95397	3	1,4-naphthoquinones		2017	2020	5.3	low	0	3	0
4-methyl-2-quinazolinamine	3			2017	2020	5.3	high	0	3	0
2-glycineamide-5-chlorophenyl-2-pyrryl ketone	3			2017	2020	5.3	high	0	3	0
wortmannin	1	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent	2005	2005	19.0	low	1	0	0
niguldipine hydrochloride	2			2019	2020	4.5	medium	0	2	0
2,5-bis(5-hydroxymethyl-2-thienyl)furan	3	thiophenes		2017	2020	5.3	low	0	3	0
ritonavir	3	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic	2017	2020	5.3	low	0	3	0
bardoxolone methyl	1	cyclohexenones		2019	2019	5.0	low	0	1	0
5-iodoindirubin-3'-monoxime	1			2007	2007	17.0	medium	1	0	0
Destruxin B	3	cyclodepsipeptide		2017	2020	5.3	high	0	3	0
2H-pyrazolo[4,3-b]quinoxalin-3-amine	2	quinoxaline derivative		2007	2013	14.0	high	1	1	0
tosylphenylalanyl chloromethyl ketone	3	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor	2017	2020	5.3	low	0	3	0
trichostatin a	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector	2019	2019	5.0	low	0	1	0
hts 466284	1	pyrazoles; pyridines; quinolines	TGFbeta receptor antagonist	2013	2013	11.0	low	0	1	0
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea	2			2007	2013	14.0	low	1	1	0
y 27632	2	aromatic amide		2007	2013	14.0	low	1	1	0
h 1152	1	isoquinolines; N-sulfonyldiazepane	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	2007	2007	17.0	medium	1	0	0
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine	2			2007	2013	14.0	high	1	1	0
6-bromoindirubin-3'-oxime	2			2007	2013	14.0	low	1	1	0
h 89	2	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide		2007	2013	14.0	low	1	1	0
purvalanol a	2	purvalanol		2007	2013	14.0	low	1	1	0
sitafloxacin	1	fluoroquinolone antibiotic; quinolines; quinolone antibiotic		2019	2019	5.0	low	0	1	0
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione	2	aminotoluene		2007	2013	14.0	high	1	1	0
2'-c-methylcytidine	3			2017	2020	5.3	low	0	3	0
evp 4593	1			2013	2013	11.0	low	0	1	0
jp-1302	3			2017	2020	5.3	medium	0	3	0
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one	3	benzodiazepine		2017	2020	5.3	high	0	3	0
tenatoprazole	3	imidazopyridine		2017	2020	5.3	low	0	3	0
s 1033	3	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	0	3	0
3-(4-pyridyl)-1h-indole	1	indoles		2013	2013	11.0	medium	0	1	0
5-[(2-fluoroanilino)methyl]-8-quinolinol	3	hydroxyquinoline		2017	2020	5.3	high	0	3	0
benidipine hydrochloride	2			2017	2020	5.5	low	0	2	0
benidipine	1			2019	2019	5.0	low	0	1	0
r 59949	2	diarylmethane		2007	2013	14.0	low	1	1	0
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one	3	quinazolines		2017	2020	5.3	high	0	3	0
chlorprothixene	3	chlorprothixene		2017	2020	5.3	medium	0	3	0
3,3',4,5'-tetrahydroxystilbene	1	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor	2007	2007	17.0	low	1	0	0
3,4-methylenedioxy-beta-nitrostyrene	1			2013	2013	11.0	low	0	1	0
jrf 12	3			2017	2020	5.3	low	0	3	0
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester	3	methoxybenzenes; substituted aniline		2017	2020	5.3	high	0	3	0
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol	1	substituted aniline		2013	2013	11.0	low	0	1	0
3-hydroxypyridine, sodium salt	3			2017	2020	5.3	high	0	3	0
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide	4	naphthalenecarboxamide		2013	2020	6.8	high	0	4	0
5-[(2-bromoanilino)methyl]-8-quinolinol	3	hydroxyquinoline		2017	2020	5.3	high	0	3	0
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide	3			2017	2020	5.3	medium	0	3	0
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline	3	aromatic amine		2017	2020	5.3	high	0	3	0
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide	3	piperidinecarboxamide		2017	2020	5.3	high	0	3	0
2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	1	dimethoxybenzene		2013	2013	11.0	medium	0	1	0
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol	3	hydroxyquinoline		2017	2020	5.3	high	0	3	0
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide	3	acetamides; anilide		2017	2020	5.3	high	0	3	0
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide	3	aromatic amide; thiophenes		2017	2020	5.3	high	0	3	0
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone	3	dimethoxybenzene		2017	2020	5.3	high	0	3	0
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide	3	aromatic amide		2017	2020	5.3	high	0	3	0
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide	3	aromatic ether		2017	2020	5.3	high	0	3	0
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione	3	maleimides		2017	2020	5.3	high	0	3	0
Src Inhibitor-1	4	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2020	6.8	high	0	4	0
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one	3	dimethoxybenzene		2017	2020	5.3	high	0	3	0
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide	3	quinolines		2017	2020	5.3	high	0	3	0
tg 003	2			2007	2013	14.0	low	1	1	0
N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline	1	benzimidazoles		2013	2013	11.0	medium	0	1	0
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine	3	pyrroles		2017	2020	5.3	high	0	3	0
thiourea	1	one-carbon compound; thioureas; ureas	antioxidant; chromophore	2007	2007	17.0	low	1	0	0
bi-78d3	3	aryl sulfide		2017	2020	5.3	medium	0	3	0
cgp 74514a	1			2013	2013	11.0	low	0	1	0
kartogenin	3			2017	2020	5.3	low	0	3	0
1,4-dimethoxy-10H-acridine-9-thione	1	acridines		2013	2013	11.0	medium	0	1	0
toremifene	1	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator	2019	2019	5.0	low	0	1	0
u 0126	1	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent	2007	2007	17.0	low	1	0	0
sf 2370	1	bridged compound; gamma-lactam; methyl ester; organic heterooctacyclic compound	antimicrobial agent; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; tropomyosin-related kinase B receptor antagonist	2013	2013	11.0	low	0	1	0
vx-745	3	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2017	2020	5.3	low	0	3	0
dasatinib	4	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2007	2020	8.2	low	1	3	0
zd 6474	3	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	0	3	0
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	2	indoles		2019	2020	4.5	high	0	2	0
uccf-029	1	organic heterotricyclic compound; organooxygen compound		2005	2005	19.0	medium	1	0	0
nih-12848	3			2017	2020	5.3	high	0	3	0
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide	3	quinazolines		2017	2020	5.3	high	0	3	0
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone	3	benzimidazoles		2017	2020	5.3	high	0	3	0
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile	3	imidazopyridine		2017	2020	5.3	high	0	3	0
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one	3	aromatic ketone		2017	2020	5.3	high	0	3	0
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester	3	oxopurine		2017	2020	5.3	high	0	3	0
gtp 14564	2	pyrazoles; ring assembly		2007	2013	14.0	high	1	1	0
sb 218078	2	indolocarbazole		2007	2013	14.0	medium	1	1	0
sto 609	1	naphthoic acid		2013	2013	11.0	low	0	1	0
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester	3	organonitrogen compound; organosulfur compound		2017	2020	5.3	high	0	3	0
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide	3	quinolines		2017	2020	5.3	high	0	3	0
7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine	1	pyrroles		2013	2013	11.0	medium	0	1	0
LSM-1924	3	organic heterotricyclic compound; organooxygen compound		2017	2020	5.3	high	0	3	0
ferrostatin-1	3	ethyl ester; primary arylamine; substituted aniline	antifungal agent; antioxidant; ferroptosis inhibitor; neuroprotective agent; radiation protective agent; radical scavenger	2017	2020	5.3	low	0	3	0
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	1	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	2013	2013	11.0	low	0	1	0
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine	3	C-nitro compound		2017	2020	5.3	high	0	3	0
rabeprazole(1-)	2	organic nitrogen anion		2019	2020	4.5	high	0	2	0
alsterpaullone	2	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor	2007	2013	14.0	low	1	1	0
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine	1	pyrazolopyrimidine	tyrosine kinase inhibitor	2013	2013	11.0	low	0	1	0
ncgc00099374	3			2017	2020	5.3	high	0	3	0
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide	3	benzamides		2017	2020	5.3	high	0	3	0
ku 55933	2			2011	2013	12.0	low	0	2	0
quercetin	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger	2007	2007	17.0	low	1	0	0
apigenin	1	trihydroxyflavone	antineoplastic agent; metabolite	2007	2007	17.0	low	1	0	0
luteolin	3	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist	2017	2020	5.3	low	0	3	0
daphnetin	1	hydroxycoumarin		2007	2007	17.0	low	1	0	0
cyclosporine	1			2019	2019	5.0	low	0	1	0
kaempferol	3	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite	2017	2020	5.3	low	0	3	0
genistein	4	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor	2007	2020	8.2	low	1	3	0
mycophenolate mofetil	3	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug	2017	2020	5.3	medium	0	3	0
bruceantin	3	triterpenoid		2017	2020	5.3	low	0	3	0
chrysin	3	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite	2017	2020	5.3	low	0	3	0
daidzein	3	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite	2017	2020	5.3	low	0	3	0
wedelolactone	1	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite	2007	2007	17.0	low	1	0	0
neticonazole	3	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor	2017	2020	5.3	medium	0	3	0
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine	3	endocannabinoid; N-acylethanolamine 22:6		2017	2020	5.3	medium	0	3	0
n-oleoylethanolamine	3	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist	2017	2020	5.3	low	0	3	0
sirolimus	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor	2013	2013	11.0	low	0	1	0
alpha-zearalenol	3	macrolide		2017	2020	5.3	high	0	3	0
as 604850	1			2013	2013	11.0	low	0	1	0
geldanamycin	1	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor	2007	2007	17.0	low	1	0	0
su 9516	5			2007	2020	8.8	medium	1	4	0
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	3	triazolopyrimidines		2017	2020	5.3	high	0	3	0
sb 277011	3			2017	2020	5.3	low	0	3	0
sb 223412	3			2017	2020	5.3	low	0	3	0
sr 59230a	3	tetralins		2017	2020	5.3	high	0	3	0
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide	4	pyrimidines		2013	2020	6.8	medium	0	4	0
kn 93	2	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector	2007	2013	14.0	low	1	1	0
kn 62	4	piperazines		2013	2020	6.8	low	0	4	0
su 6656	2			2007	2013	14.0	low	1	1	0
MeJA	3	Jasmonate derivatives		2017	2020	5.3	high	0	3	0
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)-	3			2017	2020	5.3	high	0	3	0
pd 161570	3			2017	2020	5.3	medium	0	3	0
tyrphostin ag-494	1			2007	2007	17.0	low	1	0	0
ag-490	2	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor	2007	2013	14.0	low	1	1	0
ag 112	1			2013	2013	11.0	low	0	1	0
semaxinib	1	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	0	1	0
su 11248	2	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist	2007	2017	12.0	low	1	1	0
su 11652	2	olefinic compound; organochlorine compound; oxindoles; pyrrolecarboxamide; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor	2007	2013	14.0	medium	1	1	0
6-(4-methoxyphenyl)-3-(3-thiophenyl)pyrazolo[1,5-a]pyrimidine	1	pyrimidines		2013	2013	11.0	medium	0	1	0
palbociclib	3	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2017	2020	5.3	low	0	3	0
jnj-7706621	4	sulfonamide		2013	2020	6.8	medium	0	4	0
bay 11-7082	1	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor	2013	2013	11.0	low	0	1	0
virginiamycin factor s1	3	cyclodepsipeptide; macrolide antibiotic	antibacterial drug; bacterial metabolite	2017	2020	5.3	high	0	3	0
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one	2	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2007	2013	14.0	low	1	1	0
fenoterol	2	hydrobromide	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent	2019	2020	4.5	low	0	2	0
xib 4035	3			2017	2020	5.3	high	0	3	0
gw-5074	1			2019	2019	5.0	low	0	1	0
st 638	1			2007	2007	17.0	low	1	0	0
su 1498	1	enamide; monocarboxylic acid amide; nitrile; phenols; secondary carboxamide	vascular endothelial growth factor receptor antagonist	2007	2007	17.0	low	1	0	0
monorden	1	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor	2007	2007	17.0	low	1	0	0
ml 3403	2			2007	2013	14.0	high	1	1	0
d 4476	2	imidazoles		2007	2013	14.0	medium	1	1	0
GSK3-XIII	2	aromatic amine; pyrazoles; quinazolines; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor	2007	2013	14.0	medium	1	1	0
herbimycin	1			2013	2013	11.0	medium	0	1	0
su 4312	1			2013	2013	11.0	low	0	1	0
belotecan	3	pyranoindolizinoquinoline		2017	2020	5.3	low	0	3	0
tanespimycin	1	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor	2001	2001	23.0	low	1	0	0
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole	2	aryl sulfide		2007	2013	14.0	high	1	1	0
norgestimate	3	ketoxime; steroid ester; terminal acetylenic compound	contraceptive drug; progestin; synthetic oral contraceptive	2017	2020	5.3	high	0	3	0
b 43	4	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector	2013	2020	6.8	medium	0	4	0
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine	3			2017	2020	5.3	medium	0	3	0
methiazole	3	benzimidazoles; carbamate ester		2017	2020	5.3	high	0	3	0
sb 218795	3	quinolines		2017	2020	5.3	medium	0	3	0
aminopurvalanol a	2	monochlorobenzenes; purvalanol	protein kinase inhibitor	2007	2013	14.0	high	1	1	0
bvt.948	3			2017	2020	5.3	high	0	3	0
cgk 733	1	diarylmethane		2013	2013	11.0	low	0	1	0
cgp 53353	1	phthalimides		2013	2013	11.0	low	0	1	0
fk 866	1	benzamides; N-acylpiperidine		2019	2019	5.0	low	0	1	0
a 38503	3			2017	2020	5.3	medium	0	3	0
cvt 313	2			2007	2013	14.0	medium	1	1	0
bibx 1382bs	1	substituted aniline		2007	2007	17.0	low	1	0	0
parthenolide	2	sesquiterpene lactone	drug allergen; inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug	2017	2019	6.0	medium	0	2	0
sl 327	1			2007	2007	17.0	low	1	0	0
tws 119	2	pyrroles		2007	2013	14.0	medium	1	1	0
krn 633	4			2007	2020	8.2	medium	1	3	0
((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide)	1	sulfonamide		2007	2007	17.0	low	1	0	0
c 1368	2			2007	2013	14.0	high	1	1	0
pq 401	2	quinolines		2007	2013	14.0	medium	1	1	0
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid	3	organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2017	2020	5.3	high	0	3	0
jnj 10198409	2			2007	2013	14.0	high	1	1	0
gw 501516	3	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist	2017	2020	5.3	low	0	3	0
dolastatin 10	3	1,3-thiazoles; tetrapeptide	animal metabolite; antineoplastic agent; apoptosis inducer; marine metabolite; microtubule-destabilising agent	2017	2020	5.3	low	0	3	0
spc-839	3			2017	2020	5.3	low	0	3	0
midostaurin	4	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2013	2020	6.8	low	0	4	0
valnemulin	2			2019	2020	4.5	medium	0	2	0
sb-505124	1	benzodioxole; imidazoles; methylpyridines	TGFbeta receptor antagonist	2013	2013	11.0	low	0	1	0
ic 86621	2	aromatic ketone		2013	2015	10.0	high	0	2	0
osi 930	3	aromatic amide		2017	2020	5.3	medium	0	3	0
ticagrelor	3	aryl sulfide; hydroxyether; organofluorine compound; secondary amino compound; triazolopyrimidines	P2Y12 receptor antagonist; platelet aggregation inhibitor	2017	2020	5.3	low	0	3	0
l 692585	3	peptide		2017	2020	5.3	high	0	3	0
pi103	6	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	2007	2020	8.8	low	1	5	0
nnc 26-9100	3	aminopyridine		2017	2020	5.3	medium	0	3	0
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine	3			2017	2020	5.3	high	0	3	0
PI3-Kinase alpha Inhibitor 2	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2015	2015	9.0	medium	0	1	0
y 27632, dihydrochloride, (4(r)-trans)-isomer	1			2007	2007	17.0	medium	1	0	0
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide	1	aromatic amide; thiophenes		2013	2013	11.0	low	0	1	0
tgx 221	1	pyridopyrimidine		2015	2015	9.0	low	0	1	0
tivozanib	4	aromatic ether		2013	2020	6.8	low	0	4	0
hki 272	1	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor	2019	2019	5.0	low	0	1	0
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide	3			2017	2020	5.3	medium	0	3	0
tae226	3	morpholines		2017	2020	5.3	low	0	3	0
gw0742	3	monocarboxylic acid		2017	2020	5.3	low	0	3	0
u 18666a	3	hydrochloride	antiviral agent; EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor; Hedgehog signaling pathway inhibitor; nicotinic antagonist; sterol biosynthesis inhibitor	2017	2020	5.3	low	0	3	0
sb 525334	3	quinoxaline derivative		2017	2020	5.3	low	0	3	0
bx795	3	ureas		2017	2020	5.3	low	0	3	0
azd 6244	3	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2017	2020	5.3	low	0	3	0
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea	3			2017	2020	5.3	medium	0	3	0
bay 61-3606	3	pyrimidines		2017	2020	5.3	medium	0	3	0
nu 6140	1			2013	2013	11.0	low	0	1	0
sd-208	3			2017	2020	5.3	low	0	3	0
crenolanib	3	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2017	2020	5.3	low	0	3	0
cj 033466	3			2017	2020	5.3	high	0	3	0
cc 401	3	pyrazoles; ring assembly		2017	2020	5.3	medium	0	3	0
PB28	3	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist	2017	2020	5.3	low	0	3	0
arterolane	3			2017	2020	5.3	low	0	3	0
PDGF receptor tyrosine kinase inhibitor III	1	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; quinazolines; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	medium	0	1	0
cariprazine	3			2017	2020	5.3	low	0	3	0
krp-203	3			2017	2020	5.3	high	0	3	0
regorafenib	3	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	0	3	0
at 7867	3	monochlorobenzenes; piperidines; pyrazoles	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	2017	2020	5.3	high	0	3	0
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester	3	pyrroloquinoline		2017	2020	5.3	high	0	3	0
ptc 124	3	oxadiazole; ring assembly		2017	2020	5.3	low	0	3	0
degrasyn	2			2019	2020	4.5	low	0	2	0
nu 7441	3	dibenzothiophenes		2004	2015	16.0	low	2	1	0
bi 2536	3			2017	2020	5.3	low	0	3	0
4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide	1	biphenyls		2013	2013	11.0	medium	0	1	0
fr 180204	2	pyrazoles; ring assembly		2007	2013	14.0	low	1	1	0
azd 1152	3	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug	2017	2020	5.3	medium	0	3	0
dorsomorphin	1	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor	2013	2013	11.0	low	0	1	0
ki11502	1	aromatic ether; benzamides; quinolines; thioureas	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	medium	0	1	0
carfilzomib	3	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor	2017	2020	5.3	low	0	3	0
gw 2580	2			2007	2013	14.0	low	1	1	0
idelalisib	3	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2017	2020	5.3	low	0	3	0
as 252424	1			2022	2022	2.0	low	0	0	1
cgp 57380	1	pyrazolopyrimidine		2013	2013	11.0	low	0	1	0
zstk474	1	benzimidazoles; morpholines; organofluorine compound; triamino-1,3,5-triazine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2015	2015	9.0	low	0	1	0
motesanib	3	pyridinecarboxamide		2017	2020	5.3	medium	0	3	0
pf-562,271	3	indoles		2017	2020	5.3	medium	0	3	0
gliocladin c	3			2017	2020	5.3	high	0	3	0
sb 706504	3			2017	2020	5.3	high	0	3	0
ku-0060648	4	dibenzothiophenes		2010	2020	7.5	high	1	3	0
bgt226	3	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	2017	2020	5.3	medium	0	3	0
n-desmethyldanofloxacin	3			2017	2020	5.3	high	0	3	0
rabeprazole sodium	1	organic sodium salt		2017	2017	7.0	low	0	1	0
ku 60019	1			2015	2015	9.0	low	0	1	0
azd 1152-hqpa	2	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor	2019	2020	4.5	low	0	2	0
CDN1163	3	aromatic ether; quinolines; secondary carboxamide	SERCA activator	2017	2020	5.3	medium	0	3	0
gsk 269962a	3			2017	2020	5.3	medium	0	3	0
pha 848125	3			2017	2020	5.3	medium	0	3	0
nvp-bhg712	3	benzamides		2017	2020	5.3	medium	0	3	0
(e)-3-(2,3,4,5-tetrabromophenyl)acrylic acid	1			2013	2013	11.0	medium	0	1	0
pf 04217903	3	quinolines		2017	2020	5.3	medium	0	3	0
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one	3	aromatic ketone		2017	2020	5.3	high	0	3	0
ph 797804	3	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2017	2020	5.3	low	0	3	0
srt1720	3			2017	2020	5.3	low	0	3	0
purfalcamine	3			2017	2020	5.3	high	0	3	0
bms 754807	3	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2017	2020	5.3	low	0	3	0
ponatinib	3	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	0	3	0
quizartinib	3	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor	2017	2020	5.3	low	0	3	0
PP121	3	aromatic amine; cyclopentanes; pyrazolopyrimidine; pyrrolopyridine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; tyrosine kinase inhibitor	2017	2020	5.3	medium	0	3	0
navitoclax	3	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	2017	2020	5.3	low	0	3	0
gsk 650394	3	phenylpyridine		2017	2020	5.3	medium	0	3	0
dcc-2036	3	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor	2017	2020	5.3	medium	0	3	0
cabozantinib	3	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor	2017	2020	5.3	low	0	3	0
TAK-580	3	1,3-thiazolecarboxamide; aminopyrimidine; chloropyridine; organofluorine compound; pyrimidinecarboxamide; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor	2017	2020	5.3	medium	0	3	0
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one	3	chromones		2017	2020	5.3	high	0	3	0
pf 3758309	3	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2017	2020	5.3	low	0	3	0
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	2	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor	2019	2020	4.5	low	0	2	0
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine	3	aryl sulfide; thienopyrimidine		2017	2020	5.3	high	0	3	0
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine	3	aryl sulfide; thienopyrimidine		2017	2020	5.3	high	0	3	0
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine	3	aryl sulfide; thienopyrimidine		2017	2020	5.3	high	0	3	0
pki 402	1			2015	2015	9.0	low	0	1	0
baricitinib	3	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent	2017	2020	5.3	low	0	3	0
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine	3	quinazolines		2017	2020	5.3	high	0	3	0
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone	3	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound		2017	2020	5.3	medium	0	3	0
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide	3	hydroxyquinoline		2017	2020	5.3	high	0	3	0
p505-15	3			2017	2020	5.3	high	0	3	0
mrt67307	3	aromatic amine		2017	2020	5.3	medium	0	3	0
pki 587	1			2015	2015	9.0	low	0	1	0
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide	3	piperazines		2017	2020	5.3	high	0	3	0
ribociclib	3			2017	2020	5.3	low	0	3	0
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone	3	aromatic ketone; thienopyrimidine		2017	2020	5.3	high	0	3	0
pha 793887	3	piperidinecarboxamide		2017	2020	5.3	high	0	3	0
gsk 2334470	1	indazoles		2019	2019	5.0	low	0	1	0
ml228 probe	3	1,2,4-triazines; biphenyls; pyridines; secondary amino compound	hypoxia-inducible factor pathway activator	2017	2020	5.3	high	0	3	0
pf-03882845	3			2017	2020	5.3	high	0	3	0
jq1 compound	3	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer	2017	2020	5.3	low	0	3	0
vs-5584	1			2015	2015	9.0	low	0	1	0
pf-04620110	3			2017	2020	5.3	medium	0	3	0
gsk525762a	3	benzodiazepine		2017	2020	5.3	low	0	3	0
birinapant	1	dipeptide		2019	2019	5.0	low	0	1	0
torin 1	3	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor	2017	2020	5.3	medium	0	3	0
abt-199	3	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	2017	2020	5.3	low	0	3	0
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea	3	ureas		2017	2020	5.3	medium	0	3	0
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide	3	(trifluoromethyl)benzenes		2017	2020	5.3	high	0	3	0
ncgc00242364	3	quinazolines		2017	2020	5.3	high	0	3	0
ve 821	1	aromatic amide		2011	2011	13.0	low	0	1	0
gsk1210151a	3	imidazoquinoline		2017	2020	5.3	low	0	3	0
hs-173	3			2017	2020	5.3	high	0	3	0
sr1664	3	indolecarboxamide		2017	2020	5.3	high	0	3	0
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide	3			2017	2020	5.3	high	0	3	0
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide	2	benzamides; N-acylpiperidine		2017	2020	5.5	high	0	2	0
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide	2	aminoquinoline		2017	2020	5.5	high	0	2	0
cudc-907	3			2017	2020	5.3	low	0	3	0
methacycline	1			2019	2019	5.0	low	0	1	0
lfm a13	1	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor	2007	2007	17.0	low	1	0	0
methacycline monohydrochloride	2			2017	2020	5.5	low	0	2	0
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid	3	quinolines		2017	2020	5.3	high	0	3	0
agi-5198	3			2017	2020	5.3	low	0	3	0
byl719	1	proline derivative		2022	2022	2.0	low	0	0	1
cep-32496	3			2017	2020	5.3	medium	0	3	0
epz004777	3	N-glycosyl compound		2017	2020	5.3	low	0	3	0
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid	3	organonitrogen heterocyclic compound		2017	2020	5.3	medium	0	3	0
entecavir	3	benzamides; N-acylpiperidine		2017	2020	5.3	medium	0	3	0
gkt137831	3			2017	2020	5.3	low	0	3	0
vx-509	3			2017	2020	5.3	high	0	3	0
vx-970	3	sulfonamide		2017	2020	5.3	low	0	3	0
gs-9973	3			2017	2020	5.3	high	0	3	0
sr-3029	1			2022	2022	2.0	medium	0	0	1
amg 925	3			2017	2020	5.3	high	0	3	0
gne-618	3			2017	2020	5.3	high	0	3	0
g007-lk	3			2017	2020	5.3	medium	0	3	0
volitinib	3			2017	2020	5.3	high	0	3	0
ML355	3	benzothiazoles; monomethoxybenzene; phenols; secondary amino compound; substituted aniline; sulfonamide	EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; platelet aggregation inhibitor	2017	2020	5.3	high	0	3	0
acp-196	3	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2017	2020	5.3	low	0	3	0
gsk343	3	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor	2017	2020	5.3	low	0	3	0
agi-6780	3			2017	2020	5.3	medium	0	3	0
khs101	3			2017	2020	5.3	medium	0	3	0
cb-839	3			2017	2020	5.3	low	0	3	0
gsk-j4	3	organonitrogen heterocyclic compound		2017	2020	5.3	low	0	3	0
pf-06424439	3			2017	2020	5.3	high	0	3	0
etp-46464	3			2017	2020	5.3	high	0	3	0
onc201	3			2017	2020	5.3	low	0	3	0
kai407	3			2017	2020	5.3	high	0	3	0
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	3			2017	2020	5.3	high	0	3	0
enasidenib	3	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	2017	2020	5.3	low	0	3	0
oicr-9429	3			2017	2020	5.3	medium	0	3	0
lly-507	3			2017	2020	5.3	medium	0	3	0
at 9283	3			2017	2020	5.3	medium	0	3	0
akt-i-1,2 compound	1			2013	2013	11.0	low	0	1	0
hypoxanthine	3	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite	2017	2020	5.3	low	0	3	0
clozapine	3	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic	2017	2020	5.3	low	0	3	0
1-hydroxyphenazine	3	phenazines		2017	2020	5.3	low	0	3	0
hymenialdisine	1			2007	2007	17.0	low	1	0	0
isogranulatimide	2			2007	2013	14.0	medium	1	1	0
ro 24-7429	3	benzodiazepine		2017	2020	5.3	medium	0	3	0
nintedanib	3			2017	2020	5.3	low	0	3	0
6-bromoindirubin-3'-acetoxime	1			2013	2013	11.0	medium	0	1	0
debromohymenialdisine	1			2007	2007	17.0	low	1	0	0
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide	3	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor	2017	2020	5.3	high	0	3	0
ver 52296	3	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor	2017	2020	5.3	low	0	3	0
cgs 15696	1			2022	2022	2.0	medium	0	0	1
rvx 208	3			2017	2020	5.3	low	0	3	0
bmn 673	3			2017	2020	5.3	low	0	3	0

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's
phosphoserine	1	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite	2010	2010	14.0	low	1	0
benzene	1	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent	2013	2013	11.0	low	0	1
selenious acid	1	selenium oxoacid		2013	2013	11.0	low	0	1
vanillin	1	benzaldehydes; monomethoxybenzene; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; flavouring agent; plant metabolite	2010	2010	14.0	low	1	0
3-aminobenzamide	1	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2010	2010	14.0	low	1	0
benzo(a)pyrene	1	ortho- and peri-fused polycyclic arene	carcinogenic agent; mouse metabolite	2015	2015	9.0	low	0	1
caffeine	5	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic	2006	2015	12.4	low	2	3
chlorambucil	1	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent	2007	2007	17.0	low	1	0
clioquinol	1	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator	2012	2012	12.0	low	0	1
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	2	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector	2003	2013	16.0	low	1	1
quinone	1	1,4-benzoquinones	cofactor; human xenobiotic metabolite; mouse metabolite	2015	2015	9.0	low	0	1
serine	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2010	2010	14.0	low	1	0
adenosine diphosphate	1	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite	2010	2010	14.0	low	1	0
dibenzo(a,l)pyrene	2	ortho- and peri-fused polycyclic arene	human metabolite; mutagen	2015	2020	6.5	low	0	2
gentian violet	1	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye	2015	2015	9.0	low	0	1
acetylcysteine	2	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary	2013	2014	10.5	low	0	2
deoxycytidine	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2017	2017	7.0	low	0	1
vidarabine	1	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic	2010	2010	14.0	low	1	0
camptothecin	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite	2012	2012	12.0	low	0	1
daunorubicin	1	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite	2019	2019	5.0	low	0	1
etoposide	2	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor	2005	2015	14.0	low	1	1
gemcitabine	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic	2017	2017	7.0	low	0	1
irinotecan	1	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug	2012	2012	12.0	low	0	1
cryptolepine	1	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound	anti-inflammatory agent; antimalarial; antineoplastic agent; cysteine protease inhibitor; plant metabolite	2006	2006	18.0	low	1	0
methylselenic acid	1	one-carbon compound; organoselenium compound	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor; human xenobiotic metabolite	2014	2014	10.0	low	0	1
wortmannin	3	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent	2005	2015	15.3	low	2	1
carboplatin	1			2014	2014	10.0	low	0	1
trichostatin a	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector	2011	2011	13.0	low	0	1
fludarabine	1	purine nucleoside		2010	2010	14.0	low	1	0
thiourea	1	one-carbon compound; thioureas; ureas	antioxidant; chromophore	2010	2010	14.0	low	1	0
6-(4-hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1h)-pyrimidinone	1			2017	2017	7.0	low	0	1
salinomycin	1	polyketide; spiroketal	animal growth promotant; potassium ionophore	2016	2016	8.0	low	0	1
ku 55933	5			2012	2015	10.6	low	0	5
zinostatin	1			2005	2005	19.0	low	1	0
sirolimus	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor	2013	2013	11.0	low	0	1
selenium	1	chalcogen; nonmetal atom	micronutrient	2013	2013	11.0	low	0	1
cgk 733	1	diarylmethane		2010	2010	14.0	low	1	0
ic 86621	1	aromatic ketone		2010	2010	14.0	medium	1	0
rucaparib	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2017	2017	7.0	low	0	1
nu 7441	5	dibenzothiophenes		2012	2016	10.2	low	0	5
veliparib	1	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2017	2017	7.0	low	0	1
oligonucleotides	1			2008	2008	16.0	low	1	0
calicheamicin gamma(1)i	1	calicheamicin; enediyne antibiotic; organoiodine compound	antineoplastic agent; metabolite	2011	2011	13.0	low	0	1
okadaic acid	2	ketal		2005	2013	15.0	low	1	1
cyclosporine	1			2010	2010	14.0	low	1	0
xav939	1	(trifluoromethyl)benzenes; thiopyranopyrimidine	tankyrase inhibitor	2010	2010	14.0	low	1	0
pyrimidinones	1			2017	2017	7.0	low	0	1

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's
Abnormalities, Autosome	1	2010	2010	14.0	low	1	0
Acute Confusional Senile Dementia	1	2006	2006	18.0	low	1	0
Acute Lymphoid Leukemia	1	2019	2019	5.0	low	0	1
Adenocarcinoma	2	2006	2015	13.5	low	1	1
Adenocarcinoma of Lung	1	2015	2015	9.0	low	0	1
Adenocarcinoma, Basal Cell	2	2006	2015	13.5	low	1	1
Adipocere	1	2006	2006	18.0	low	1	0
Alzheimer Disease	1	2006	2006	18.0	low	1	0
Angiogenesis, Pathologic	1	2015	2015	9.0	low	0	1
Astrocytoma, Grade IV	2	2010	2015	11.5	low	1	1
B-Cell Chronic Lymphocytic Leukemia	2	2005	2010	16.5	low	2	0
Benign Neoplasms	2	2013	2017	9.0	low	0	2
Benign Neoplasms, Brain	2	2011	2015	11.0	low	0	2
Bone Cancer	1	2016	2016	8.0	low	0	1
Bone Neoplasms	1	2016	2016	8.0	low	0	1
Brain Neoplasms	2	2011	2015	11.0	low	0	2
Breast Cancer	2	2010	2010	14.0	low	2	0
Breast Neoplasms	2	2010	2010	14.0	low	2	0
Cancer of Cervix	1	2020	2020	4.0	low	0	1
Cancer of Colon	1	2012	2012	12.0	low	0	1
Cancer of Liver	2	2015	2020	6.5	low	0	2
Cancer of Lung	4	2006	2015	12.5	low	2	2
Cancer of Ovary	2	2005	2014	14.5	low	1	1
Cancer of Pancreas	2	2012	2017	9.5	low	0	2
Cancer of Skin	1	2013	2013	11.0	low	0	1
Carcinoma, Ductal, Pancreatic	1	2012	2012	12.0	low	0	1
Carcinoma, Hepatocellular	1	2020	2020	4.0	low	0	1
Carcinoma, Non-Small Cell Lung	1	2015	2015	9.0	low	0	1
Carcinoma, Non-Small-Cell Lung	1	2015	2015	9.0	low	0	1
Carcinoma, Pancreatic Ductal	1	2012	2012	12.0	low	0	1
Chromosomal Instability	1	2010	2010	14.0	low	1	0
Chromosome Instability Syndromes	1	2010	2010	14.0	low	1	0
Chronic Hepatitis B	1	2019	2019	5.0	low	0	1
Colonic Neoplasms	1	2012	2012	12.0	low	0	1
Colorectal Cancer	1	2015	2015	9.0	low	0	1
Colorectal Neoplasms	1	2015	2015	9.0	low	0	1
Encephalopathy, Toxic	1	2012	2012	12.0	low	0	1
Glial Cell Tumors	1	2011	2011	13.0	low	0	1
Glioblastoma	2	2010	2015	11.5	low	1	1
Glioma	1	2011	2011	13.0	low	0	1
Granulocytic Leukemia	1	2012	2012	12.0	low	0	1
Hepatitis B, Chronic	1	2019	2019	5.0	low	0	1
Hepatocellular Carcinoma	1	2020	2020	4.0	low	0	1
Invasiveness, Neoplasm	1	2015	2015	9.0	low	0	1
Kahler Disease	1	2009	2009	15.0	low	1	0
Leukemia, Lymphocytic, Chronic, B-Cell	2	2005	2010	16.5	low	2	0
Leukemia, Lymphocytic, T Cell	1	2012	2012	12.0	low	0	1
Leukemia, Myeloid	1	2012	2012	12.0	low	0	1
Leukemia, T-Cell	1	2012	2012	12.0	low	0	1
Liver Neoplasms	2	2015	2020	6.5	low	0	2
Lung Adenocarcinoma	1	2015	2015	9.0	low	0	1
Lung Neoplasms	4	2006	2015	12.5	low	2	2
Multiple Myeloma	1	2009	2009	15.0	low	1	0
Neoplasms	2	2013	2017	9.0	low	0	2
Neuroblastoma	2	2012	2015	10.5	low	0	2
Osteogenic Sarcoma	1	2016	2016	8.0	low	0	1
Osteosarcoma	1	2016	2016	8.0	low	0	1
Ovarian Neoplasms	2	2005	2014	14.5	low	1	1
Pancreatic Neoplasms	2	2012	2017	9.5	low	0	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma	1	2019	2019	5.0	low	0	1
Skin Neoplasms	1	2013	2013	11.0	low	0	1
Uterine Cervical Neoplasms	1	2020	2020	4.0	low	0	1

Safety/Toxicity (4)

Article	Year
The effect of inhibitors of phosphatidylinositol 3-kinase-related kinases on dibenzo[def,p]chrysene genotoxicity measured by γH2AX levels and neutral comet assay in HepG2 human hepatocellular cancer cells. Toxicology in vitro : an international journal published in association with BIBRA, , Volume: 63	2020
The modulating effect of ATM, ATR, DNA-PK inhibitors on the cytotoxicity and genotoxicity of benzo[a]pyrene in human hepatocellular cancer cell line HepG2. Environmental toxicology and pharmacology, , Volume: 40, Issue:3	2015
The influence of ATM, ATR, DNA-PK inhibitors on the cytotoxic and genotoxic effects of dibenzo[def,p]chrysene on human hepatocellular cancer cell line HepG2. Mutation research. Genetic toxicology and environmental mutagenesis, , Volume: 791	2015
Activation of DNA damage repair pathways in response to nitrogen mustard-induced DNA damage and toxicity in skin keratinocytes. Mutation research, , Volume: 763-764

Pharmacokinetics (1)

Article	Year
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. British journal of cancer, , Oct-31, Volume: 93, Issue:9	2005

Bioavailability (3)

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5	2019
Highly predictive and interpretable models for PAMPA permeability. Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3	2017
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. British journal of cancer, , Oct-31, Volume: 93, Issue:9	2005

Dosage (1)

Article	Year
ATM is the predominant kinase involved in the phosphorylation of histone H2AX after heating. Journal of radiation research, , Volume: 51, Issue:4	2010